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Figure 1. Stages in the process of normal and abnormal wound healing. Wound healing can be divided into 
four stages: Clotting and coagulation (not shown), inflammatory cell migration, fibroblast migration, proliferation 
and activation followed by tissue remodeling and/or resolution. Dysregulation of one of these stages or persistent 
lung injury can lead to tissue fibrosis. (Figure modified from Wynn et al., 2011). 


α
Figure 2. Pathway of collagen synthesis and maturation. The process starts in the cell with the transcription 
and translation of procollagen. Procollagen is co-translationally translocated into the rER where PTMs are 
executed. Several enzymes and molecular chaperones like HSP47 and FKBP10 assist in procollagen maturation 
and triple helical folding. Procollagen is translocated to the golgi via vesicles and further modified. After secretion 
propeptides are cleaved resulting in tropocollagen. Fibrils assemble in an entropy-driven process. Fibrils form into 
fibers and finally build fiber bundles. Crosslinking of the telopeptides of tropocollagen is catalyzed by lysyl 
oxidases and transglutaminase 2. (Figure adapted from Chen et al, 2009) 



Table 1. Key recommendations on pharmacological treatment of IPF according to current guidelines (adapted 
from Kreuter, et al., 2015) 
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Figure 3. PPIase activity. PPIases catalyze the cis/trans isomerization of proline residues. (Figure adapted from 
Lu, et al., 2007)  
Figure 4. Examples of FKBP members of each subgroup. FKBP1 and FKBP1B belong to the cytoplasmatic 
FKBPs. FKBP3 and 15 are nuclear FKBPs. FKBP4, 5, 6, 8 contain a tetratricopeptide (TRP) domain and are 
therefore grouped as TRP-domain containing FKBPs. FKBP7, 9, 10, 11, 14 belong to the secretory pathway 
FKBPs. (Figure adapted from Rulten, et al., 2006). 
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Abstract
Rationale: Increased abundance and stiffness of the extracellular
matrix, in particular collagens, is a hallmark of idiopathic pulmonary
fibrosis (IPF). FK506-binding protein 10 (FKBP10) is a collagen
chaperone, mutations of which have been indicated in the reduction
of extracellular matrix stiffness (e.g., in osteogenesis imperfecta).
Objectives:To assess the expression and function of FKBP10 in IPF.
Methods:We assessed FKBP10 expression in bleomycin-
induced lung fibrosis (using quantitative reverse
transcriptase–polymerase chain reaction, Western blot, and
immunofluorescence), analyzed microarray data from 99
patients with IPF and 43 control subjects from a U.S. cohort,
and performed Western blot analysis from 6 patients with IPF
and 5 control subjects from a German cohort. Subcellular
localization of FKBP10 was assessed by immunofluorescent
stainings. The expression and function of FKBP10, as well as its
regulation by endoplasmic reticulum stress or transforming
growth factor-b1, was analyzed by small interfering
RNA–mediated loss-of-function experiments, quantitative reverse
transcriptase–polymerase chain reaction, Western blot, and
quantificationof secreted collagens in the lung and inprimaryhuman
lung fibroblasts (phLF). Effects on collagen secretion were compared
with those of the drugs nintedanib and pirfenidone, recently
approved for IPF.
Measurements and Main Results: FKBP10 expression was
up-regulated in bleomycin-induced lung fibrosis and IPF.
Immunofluorescent stainings demonstrated localization to
interstitial (myo)fibroblasts andCD681macrophages. Transforming
growth factor-b1, but not endoplasmic reticulum stress, induced
FKBP10 expression in phLF. The small interfering RNA–mediated
knockdown of FKBP10 attenuated expression of profibrotic
mediators and effectors, including collagens I and V and a-smooth
muscle actin, on the transcript and protein level. Importantly, loss of
FKBP10 expression significantly suppressed collagen secretion by
phLF.
Conclusions: FKBP10 might be a novel drug target for IPF.
Keywords: FKBP65; peptidyl-prolyl isomerase; lung fibrosis;
collagen cross-linking; extracellular matrix
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Idiopathic pulmonary fibrosis (IPF) is
the most fatal interstitial lung disease,
with a 5-year survival rate of 30 to 50%
and few treatment options (1). The
etiology of IPF is poorly understood.
The current concept involves repeated
alveolar injuries of unclear nature,
providing signals for fibroblast activation,
proliferation, and differentiation to
myofibroblasts (2–6). The latter overgrow
the delicate alveolar lung tissue and
secrete increased amounts of extracellular
matrix (ECM) proteins. According to
a recently published study, the ECM
appears to play a major role not only
in the composition but also in the
maintenance of the fibrotic phenotype
in IPF, contributing to the irreversibility
of the disease (7). Therefore, matrix
and matrix-processing enzymes will
provide promising novel drug targets
for IPF. For instance, inhibition of the
collagen cross-linking enzyme lysyl
oxidase-like 2 (LOXL2) is currently
investigated as an IPF treatment option
in a phase II trial (8).
Pirfenidone and nintedanib, two
drugs recently approved by the U.S.
Food and Drug Administration for IPF
therapy, decelerate but do not attenuate
disease progression in patients with IPF,
by decreasing lung function decline.
They also show considerable side effects,
and their mechanism of action is
incompletely understood (9, 10). As
such, the need to identify novel drug
targets for IPF remains imperative, as
we require alternative treatment options
for nonresponders, cell-type–specific
targeted therapy, and combination
therapy options.
The intracellular chaperone
FK506-binding protein 10 (FKBP10,
also termed FKBP65) has been reported
to directly interact with collagen I (11).
FKBP10 belongs to the FKBP subfamily
of immunophilins, molecular chaperones
with peptidyl-prolyl isomerase activity,
which bind the immunosuppressive
drug FK506 (tacrolimus) (12, 13).
Collagen triple helix formation heavily
relies on proline isomerization to
trans-proline as a prerequisite of linear
chain assembly (14). Mutations in
FKBP10 lead to collagen-related disorders
such as osteogenesis imperfecta, and
studies in the last 4 years have suggested
an association of these mutations with
attenuated collagen secretion and
diminished collagen I cross-linking in
dermal fibroblasts and bone (15–18). A
recent study showed that Fkbp102/2 mouse
embryos are postnatally lethal and display
reduced collagen cross-linking in calvarial
bone (19).
Given that FKBP10 is a collagen-
processing enzyme with potential impact
on ECM protein secretion and cross-linking,
we sought to assess its role in IPF. We
analyzed FKBP10 expression in lungs of
mice subjected to bleomycin and patients
with IPF. Loss-of-function studies were
performed in primary human lung
fibroblasts (phLF) to investigate the effect
of FKBP10 on ECM protein synthesis and
secretion.
Methods
For more details on methods, see the online
supplement. Statistical analysis was
performed in GraphPadPrism 5 (GraphPad
Software, San Diego, CA). Results are given
as mean6 SEM, and paired t test was used
for statistical analysis, if not mentioned
otherwise.
Induction and Measurement of
Murine Pulmonary Fibrosis
Pulmonary fibrosis was induced in female
C57BL/6 mice (10–12 wk old) by a single
intratracheal instillation of 50 ml of
bleomycin (3 U/kg; Sigma Aldrich,
Taufkirchen, Germany) dissolved in sterile
saline and applied using the MicroSprayer
Aerosolizer, Model IA-1C (Penn-Century,
Wyndmoor, PA). Control mice were
instilled with 50 ml of saline. After
instillation, mice were kept for 14, 28, and
56 days. Before death, mice were
anesthetized with ketamine/xylazine
followed by lung function measurement
and tissue harvesting as previously
described (20). Fibrosis was further assessed
by bronchoalveolar lavage cell counts
and histology evaluation. All animal
experiments were conducted under strict
governmental and international guidelines
and were approved by the local government
for the administrative region of Upper
Bavaria, Germany.
Gene Expression Data
Data for FKBP10 in IPF lungs (n = 99) and
normal histology control lungs (n = 43) was
extracted from the gene expression
microarray data generated by us on lung
samples obtained from the National Lung,
Heart, and Blood Institute–funded Tissue
Resource Consortium, as described previously
(21, 22). Gene expression microarray data
(Agilent Technologies, Santa Clara, CA), and
associated clinical data are available on the
Lung Genomics Research Consortium
website (https://www.lung-genomics.org/
research/) as well as on accession number
GSE47460 or the Lung Tissue Research
Consortium website (http://www.ltrcpublic.
com). Significance was calculated using t
statistics, and multiple testing was controlled
by the false discovery rate method at 5% (23).
Human Material
Resected human lung tissue and lung
explant material were obtained from the
Asklepios biobank for lung diseases at the
Comprehensive Pneumology Center.
Biopsies were obtained from six patients
with IPF (usual interstitial pneumonia
pattern, mean age 546 9 yr, five men, one
woman). All participants gave written
informed consent, and the study was
approved by the local ethics committee of
Ludwig-Maximilians University of Munich,
Germany.
Isolation and Culture of phLF
For FKBP10 knockdown, phLF were
isolated from IPF biopsies (n = 4), the
adjacent normal region of a lung tumor
resection (n = 2), and donor tissue (n = 3).
For more details, see the online supplement.
At a Glance Commentary
Scientific Knowledge on the
Subject: Accumulation of
extracellular matrix plays an important
role in idiopathic pulmonary fibrosis
(IPF) disease progression. Deficiency of
the chaperone FK506-binding protein
10 (FKBP10) has been reported to
attenuate collagen secretion and
decrease extracellular collagen
cross-linking in, for example,
osteogenesis imperfecta.
What This Study Adds to the
Field: FKBP10 is specifically
up-regulated in interstitial fibroblasts
in IPF. Inhibition of FKBP10 in primary
IPF fibroblasts attenuates gene
expression of various profibrotic genes
and decreases collagen secretion.
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Treatment of phLF with Transforming
Growth Factor-b1, Nintedanib, or
Pirfenidone
Cells were seeded at a density of 20,000 to
25,000 cells/cm2, starved for 24 hours in
Dulbecco’s modified Eagle medium/F12
with 0.5% fetal bovine serum and 0.1 mM
2-phospho-L-ascorbic acid, followed by
treatment with the indicated concentrations
of transforming growth factor (TGF)-b1
(R&D Systems, Minneapolis, MN),
nintedanib, and pirfenidone (both Selleck,
Houston, TX) in starvation medium for the
indicated time points. For more details, see
the online supplement.
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Figure 1. FK506-binding protein 10 (FKBP10) is up-regulated in a mouse model of bleomycin-induced lung fibrosis. (A) Representative Masson trichrome
staining demonstrating that increased collagen deposition peaked at Day 14 and was gradually lost afterward. Bottom row shows magnification of the
boxed areas in the top row. Upper scale bar = 1,000 mm; lower scale bar = 100 mm. (B) Bleomycin instillation led to a significant decrease in lung compliance
at Day 14, which was completely restored after 56 days. (C) FKBP10 gene expression was up-regulated at Day 14 after bleomycin instillation. (D)
Representative Western blot showing that FKBP10 levels in total lung homogenate were significantly increased at Day 14 after bleomycin instillation; HeLa
lysate was used as positive control. (E) Quantification by densitometric analysis demonstrating that FKBP10 levels returned to baseline at Day 28 and Day 56.
Data shown are mean6 SEM, and a two-tailed Mann-Whitney test was used for statistical analysis for comparison between bleomycin groups (Bleo) at different
time points and phosphate-buffered saline (PBS) control vs. bleomycin for each time point. Actb =b-actin as loading control. Gapdh = glyceraldehyde phosphate
dehydrogenase. **P,0.01, ***P,0.001.
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Transfection of phLF
Cells were reverse transfected either with
human FKBP10 small interfering RNA
(siRNA) (s34171; Life Technologies,
Carlsbad, CA) or negative control siRNA
No. 1 (Life Technologies). Twenty-four hours
after transfection, cells were starved for
another 24 hours in Dulbecco’s modified
Eagle medium/F-12 including 0.5% fetal
bovine serum and 0.1 mM 2-phospho-L-
ascorbic acid, followed by treatment with
2 ng/ml TGF-b1 in starvation medium.
Twenty-four and 48 hours after beginning
the TGF-b1 treatment, cells and cell culture
supernatants were harvested for RNA and
protein analysis. In total, eight completely
independent knockdowns were performed in
eight different human primary fibroblast
lines.
After 24 hours of siRNA transfection,
forward transfection with the mothers
against decapentaplegic homolog (SMAD)
signaling luciferase reporter plasmid was
performed in three different cell lines with
pGL3-CAGA(9)-luc (24) or pGL3 control
vector (Promega, Madison, WI). After
incubation for 6 hours, cells were starved
for 18 hours, followed by treatment with
2 ng/ml TGF-b1. Luminescence was
recorded in a TriStar LB 941 Multimode
Reader (Berthold Technologies, Bad
Wildbad, Germany), and results were
normalized to pGL3 control luciferase activity.
For more details, see the online
supplement.
Real-Time Quantitative Reverse
Transcriptase Polymerase Chain
Reaction Analysis
Relative transcript abundance of a gene
is expressed as 2DCt values (DCt = Ct
target
2
Ct
reference) or as fold change derived from the
relevant DDCt values, using 2
2(DDCt). For
specific gene amplification, primers listed in
Table E1 in the online supplement were used.
Glyceraldehyde phosphate dehydrogenase
(GAPDH) and hypoxanthine-guanine
phosphoribosyltransferase (HPRT) were used
as endogenous controls for standardization of
relative mRNA expression in mice and phLF,
respectively. For more technical details on
RNA isolation and quantitative reverse
transcriptase polymerase chain reaction, see
the online supplement.
Protein Isolation and Western Blot
Analysis
See online supplement.
Quantification of Secreted Collagen
For quantification of total secreted collagen,
the Sircol assay was performed according to
manufacturer’s instructions (Biocolor,
Carrickfergus, UK).
For specific quantification of secreted
collagen I, collagens were precipitated from
cell culture supernatant as follows: Proteins
were precipitated with 0.2 g/ml ammonium
sulfate and incubated on ice for 30 minutes,
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Figure 2. FK506-binding protein 10 (FKBP10) is up-regulated in idiopathic pulmonary fibrosis (IPF). (A) Heat map of FKBP10 gene expression, extracted
from microarray data of normal histology control (n = 43) and samples from patients with IPF (n = 99). Every column corresponds to a patient. Increases
and decreases are denoted in increasing shades of yellow and purple, respectively, and gray is unchanged (false discovery rate, 5%). (B) Box-and-
whisker plot for FKBP10 gene expression data. The difference is highly significant (***P, 13 1027). (C) Western blot analysis of total lung tissue
homogenate showed up-regulation of FKBP10 in patients with IPF relative to donor samples in an independent cohort. (D) Densitometric analysis of the
Western blot showed that FKBP10 up-regulation in IPF is highly significant. Data shown are mean6 SEM, and a two-tailed Mann-Whitney test was used
for statistical analysis (**P, 0.01). a-SMA = a-smooth muscle actin; ACTB = b-actin as loading control.
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followed by centrifugation at 20,0003 g
at 48C for 30 minutes. The pellet was
dissolved in 0.1 M acetic acid containing
0.1 mg/ml pepsin (Thermo Fisher
Scientific, Waltham, MA) and incubated
overnight at 48C. Then, 5 M NaCl was
added to yield a final concentration of
0.7 M, followed by incubation on ice
for 30 minutes and centrifugation at
20,0003 g at 48C for 30 minutes. The
pellet containing collagen I was
resuspended in 0.1 M acetic acid and
analyzed by immunoblotting.
Immunofluorescent and Masson
Trichrome Stainings
Cultured phLF were seeded on coverslips,
and immunostaining was performed as
described previously (25). For staining of
tissue sections, human and murine lung
tissue was fixed in 10% formalin before
paraffin embedding. Three-micron sections
were prepared and mounted on slides,
followed by deparaffinization and
immunofluorescent staining or Masson
trichrome staining according to a standard
protocol. For more details, see the online
supplement.
Subcellular Fractionation
Protein fractionation was performed
with a Subcellular Protein Fractionation
Kit for Cultured Cells (Thermo Fisher
Scientific) according to the manufacturer’s
instructions. Purity of the fractions was
assessed using the following marker
proteins for Western blot analysis of the
obtained fractions: calreticulin and protein
disulfide isomerase 3 (PDIA3) for the
membrane extract, glyceraldehyde
phosphate dehydrogenase (GAPDH) for
the cytosolic extract, and lamin A/C for the
nuclear and chromatin-bound extract.
Results
FKBP10 Expression Is Increased in
Lung Fibrosis
We first studied FKBP10 expression in the
mouse model of bleomycin-induced lung
fibrosis. Bleomycin instillation led to
increased ECM deposition, as demonstrated
by Masson trichrome staining, and
a significant decrease in lung compliance
at Day 14, which was completely restored
after 56 days (Figures 1A and 1B). Western
blot analysis showed a clear increase of
FKBP10 protein levels in total lung lysates
at Day 14 after instillation of bleomycin
(Figure 1D). After resolution of fibrosis,
at Day 56, FKBP10 expression had returned
to baseline levels (cf. Figures 1A, 1B,
and 1E). With a fold change of 3.6,
up-regulation of FKBP10 at Day 14
occurred in part on the transcriptional
level (Figure 1C).
Next, we studied FKBP10 gene
expression in IPF. Analysis of microarray
data of 99 IPF samples and 43 normal
histology control samples revealed
significant up-regulation of FKBP10 (fold
change, 1.7; false discovery rate, 5%;
P, 13 1027) (Figures 2A and 2B). Up-
regulation of FKBP10 was confirmed on the
protein level using lung homogenates from
patients with IPF of an independent
cohort: FKBP10 was highly increased in
comparison with donor samples (Figures
2C and 2D). Moreover, FKBP10 levels
appeared to correlate with levels of
a-smooth muscle actin (a-SMA), a marker
of myofibroblasts (Figure 2C).
FKBP10 Is Expressed in Interstitial
Fibroblasts, Including Myofibroblasts
Immunofluorescent stainings of lung
tissue sections from the bleomycin-treated
mice and patients with IPF confirmed
increased expression of FKBP10 in
fibrotic lungs, with little staining of FKBP10
in phosphate-buffered saline–instilled
control mice or donor lungs. FKBP10
expression was predominantly localized
to interstitial fibroblasts, as evidenced by
colocalization with a-SMA (Figures 3
and 4A) or desmin (Figure 4A), both
markers of myofibroblasts. In addition,
a fraction of FKBP10-expressing cells
were found to be interstitial macrophages
(evidenced by CD681 staining; Figure 4B).
PBS            Bleo   
FKBP10
α-SMA
DAPI
FKBP10
T1α
DAPI
FKBP10
TTF1
DAPI
100 μm
Figure 3. FK506-binding protein 10 (FKBP10) is expressed in interstitial fibroblasts, including
myofibroblasts, in a mouse model of bleomycin-induced lung fibrosis. Immunofluorescent stainings of
paraffin sections from control (phosphate-buffered saline [PBS], left panels) and bleomycin-treated
(Bleo, right panels) mice at Day 14 after bleomycin instillation. Representative Fkbp10 immunostaining
is shown in red, a-smooth muscle actin (a-SMA), podoplanin (T1a), or thyroid transcription factor 1
(TTF1) in green, and 49,6-diamidino-2-phenylindole (DAPI) in blue, as indicated on the right side.
White squares in the Bleo stainings are shown enlarged to the right. Sections shown are
representative stainings from three PBS- and three bleomycin-treated mice.
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In contrast, FKBP10 did not colocalize with
T1a (AT1 cells) or TTF1 (AT2 cells)
(Figures 3 and 4A).
FKBP10 Is an Endoplasmic Reticulum
Resident Protein but Not
Up-regulated by ER Stress in Primary
Human Lung Fibroblasts
In immunofluorescent stainings of phLF,
FKBP10 localized mainly to the cytoplasm
and showed colocalization with PDIA3, an
endoplasmic reticulum (ER)-resident
protein (Figure 5A). In some cells, positive
FKBP10 staining was also observed in the
nucleus. In contrast, costaining with
a marker for the Golgi apparatus, Golgin
subfamily A member 1 (GOLGA1) showed
no colocalization (Figure 5B). Subcellular
fractionation of phLF resulted in a clear
enrichment of FKBP10 in the ER/
membrane extract (Figure 5C).
Additionally, FKBP10 was also weakly
detected in the cytosolic and the nuclear
extract.
Although tunicamycin and
thapsigargin up-regulated the ER
stress markers BiP, ATF4, and CHOP,
FKBP10 levels were drastically decreased
by both (see Figure E1 in the online
supplement). FKBP10 usually migrated
at approximately 70 kD, but in the
presence of tunicamycin an additional
FKBP10 band appeared at approximately
65 kD, in agreement with the theoretical
size of the unmodified protein
(cf. Figure E1A).
TGF-b1 Up-regulates FKBP10
Expression in phLF
TGF-b1 induced FKBP10 expression in
a dose-dependent manner, with a clearly
visible up-regulation for concentrations of
1 ng/ml and higher after 48 hours of
treatment (Figure 6A). Efficacy of TGF-b1
treatment was confirmed by Western blot
analysis of phosphorylated and total
SMAD3 (Figure 6A). From these initial
experiments, an effective concentration of
2 ng/ml TGF-b1 was derived and used in
the following FKBP10 knockdown
experiments, where the TGF-b1 effect on
FKBP10 expression was also quantified
(Figure 6B). Results in Figure 6B are based
on results with control siRNA from the
loss-of-function experiments (cf. Figure 6C
for a representative Western blot).
Induction of FKBP10 expression by
TGF-b1 was already observed at transcript
level (Figure E2).
Donor           IPF
100 μm FKBP10
α-SMA
DAPI
FKBP10
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FKBP10
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FKBP10
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FKBP10
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Figure 4. FK506-binding protein 10 (FKBP10) is expressed in interstitial fibroblasts,
including myofibroblasts, and interstitial CD681 macrophages in human idiopathic pulmonary
fibrosis (IPF). Representative immunofluorescent stainings of paraffin sections from donor
(left panels) and IPF tissue (right panels). Representative FKBP10 immunostaining is always shown in red
and 49,6-diamidino-2-phenylindole (DAPI) in blue. (A) Representative immunofluorescent costainings with
a-smooth muscle actin (a-SMA), desmin, podoplanin (T1a), and thyroid transcription factor 1 (TTF1)
in green show FKBP10 expression in interstitial fibroblasts but not in alveolar epithelial cells.
White squares in the IPF stainings are shown enlarged to the right. Scale bar= 100 mm. (B)
Representative immunofluorescent costainings with CD68 show FKBP10 expression in interstitial
macrophages (indicated by white arrows). Sections shown are representative stainings from three
donors and three patients with IPF. Scale bar= 50 mm.
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Loss of FKBP10 in IPF Fibroblasts
Attenuates ECM Protein Synthesis
and Decreases Levels of Secreted
Collagen Independent of TGF-b
Signaling
The siRNA-mediated knockdown of
FKBP10 in IPF fibroblasts showed
significant down-regulation of collagen I,
collagen V, and fibronectin protein levels
in crude cell lysates after 48 hours of
TGF-b1 treatment (Figures 6C and 6D).
Interestingly, TGF-b1 partly counteracted
this effect for collagen I, but not for
collagen V or fibronectin (Figure 6D).
Moreover, levels of the myofibroblast
marker a-SMA were also significantly
decreased by knockdown of FKBP10 in the
presence of TGF-b1 (Figure 6D, bottom
right panel). The effects observed for
collagen I and V manifested at transcript
level already and also transcription of the
TGF-b target gene PAI1 were decreased by
knockdown of FKBP10, suggestive of an
effect on overall TGF-b signaling
(Figure 7A). However, the corresponding
TGF-b–induced transcript fold changes
did not indicate attenuation of TGF-b
signaling in the FKBP10 knockdown
(Figure 7B), and neither a Smad signaling
luciferase reporter assay (Figure 7C) nor
analysis of SMAD 3 phosphorylation or
protein levels (Figure 7D and Figure E3)
showed an appreciable effect of FKBP10
knockdown on canonical TGF-b signaling.
Finally, we assessed levels of secreted
collagen in these experiments by two
approaches. First, specifically collagen type I
levels were semiquantified using Western
blot analysis followed by densitometry
(Figures 8A and 8B); second, total secreted
collagen was quantified using the Sircol
assay (Figure 8C). Both approaches showed
significant decreases of secreted collagen in
the FKBP10 knockdown in absence and
presence of TGF-b1.
In our efforts to interpret the relevance
of FKBP10 knockdown in IPF fibroblasts in
the context of currently approved IPF
therapeutics, we used the same experimental
setup to address inhibition of total collagen
secretion in IPF fibroblasts by nintedanib
and pirfenidone. Importantly, FKBP10
knockdown significantly decreased total
collagen secretion by about 20%, in an
amount similar to the effects observed with
nintedanib, whereas we did not observe any
effect of pirfenidone on total collagen
secretion (Figure 9).
Discussion
In the present study, we show that FKBP10 is
up-regulated in bleomycin-induced lung
fibrosis and IPF. FKBP10 is predominantly
expressed in interstitial (myo)fibroblasts
and CD681 macrophages. TGF-b1, but not
ER stress, induced FKBP10 expression in
phLF. Loss of FKBP10 in phLF led to
attenuation of collagen synthesis and
secretion and reduced the expression of
a-SMA and PAI1 independent of the
TGF-b signaling pathway. Finally, FKBP10
knockdown inhibited collagen secretion with
an efficiency similar to that of nintedanib.
FKBP10 was up-regulated in the mouse
model of bleomycin-induced lung fibrosis
and returned to baseline with resolution of
the disease (Figure 1). In agreement,
a previous study has indicated
up-regulation of FKBP10 mRNA during
bleomycin-induced lung injury (26). In this
study, however, analysis was restricted to
FKBP10
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A
B C
Figure 5. FK506-binding protein 10 (FKBP10) is mainly an endoplasmic reticulum (ER)-resident
protein and does not localize to the Golgi apparatus. (A) Immunostaining of FKBP10 and the
ER-marker protein disulfide isomerase A3 (PDIA3) is shown in red and green, respectively. 49,6-
diamidino-2-phenylindole (DAPI) staining is shown in blue. The white square was chosen as the
region of interest and enlarged to the right. Arrows in the region of interest depict examples for
colocalization of FKBP10 and PDIA3. While the staining shown to the left is an extended-focus picture
generated from a z-stack, the enlarged figure to the right shows one focal plane from the z-stack only.
(B) Immunostaining of FKBP10 and the Golgi-marker protein Golgin subfamily A member 1 is shown
in red and green, respectively. DAPI staining is shown in blue. The presented staining is an
extended-focus picture generated from a z-stack. (C) Western blot analysis of subcellular
fractionation of primary human lung fibroblasts. FKBP10 is enriched in the membrane extract
(ME), similar to the ER-resident proteins calreticulin (CALR) and PDIA3. FKBP10 was additionally
found in the cytosolic extract (CE) and the nuclear extract (NE) but not in the chromatin-bound
fraction (CB). Lamin A/C and glyceraldehyde phosphate dehydrogenase (GAPDH) were used as
marker proteins for NE/CB and CE, respectively.
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Day 10 after bleomycin administration, and
up-regulation was merely assessed at
transcript level. We clarify that FKBP10
overexpression occurs on the protein level
and correlated with the fibrotic phase and
lung function, both aspects of importance
for the translation of these results to IPF,
a state of presumably irreversible fibrosis.
Most importantly, we show for the first
time that FKBP10 expression is increased
in IPF (Figure 2). This appears to be
a universal phenomenon, as we discovered
this in two completely independent cohorts,
one in the United States and one in Europe,
strongly arguing for an important function
of FKBP10 in IPF. Immunofluorescent
stainings of fibrotic mouse and IPF tissue
sections revealed strong FKBP10 expression
by interstitial fibroblasts, including
myofibroblasts, the major ECM-producing
cell type in fibrotic lung disease (Figures 3
and 4), indicating that FKBP10 might have
a function in ECM protein synthesis in
phLF. Notably, many myofibroblasts, both
in the mouse model as well as in the IPF
sections, were FKBP10-negative,
highlighting the phenotypic diversity of
interstitial mesenchymal cell types in
fibrosis.
The subcellular localization provided
an important clue for FKBP10 function in
fibroblasts, as FKBP10 substrates proposed
in the literature include not only ECM
protein precursors, such as procollagen I or
tropoelastin (11, 27), but also cytosolic
proteins, such as HSP90 and c-Raf-1 (28).
A
ACTB
pSMAD3
SMAD3
TGF-β
ctrl
FKBP10
ctrl
TGF-β
B
TGF-β
FKBP10 siRNA
–
–
–
–
–
+
–
+
+
–
+
–
+
+
+
+
24h 48h
FKBP10
C
24h 48h
D
ctrl siRNA
FKBP10 siRNA
–
–
–
–
–
+
–
+
+
–
+
–
+
+
+
+
24h 48h
–
–
–
–
–
+
–
+
+
–
+
–
+
+
+
+
24h 48h
**
*
*
*
*
**
–
–
–
–
–
+
–
+
+
–
+
–
+
+
+
+
24h 48h
Collagen I
Collagen V
Fibronectin
α-SMA
ACTB
0.0
0.5
1.0
1.5
2.0
2.5
re
la
tiv
e 
ba
nd
 in
te
ns
ity
(F
K
B
P
10
/β
-a
ct
in
)
*
FKBP10
0
2
4
6
8
re
la
tiv
e 
ba
nd
 in
te
ns
ity
(C
ol
l I
/β
-a
ct
in
)
Collagen I
0
2
4
6
8
10
re
la
tiv
e 
ba
nd
 in
te
ns
ity
(C
ol
l V
/β
-a
ct
in
)
Collagen V
*
0
2
4
6
8
re
la
tiv
e 
ba
nd
 in
te
ns
ity
(F
N
1/
β
-a
ct
in
)
*
0
50
100
150
re
la
tiv
e 
ba
nd
 in
te
ns
ity
(α
-S
M
A
/β
-a
ct
in
)Fibronectin α-SMA
TGF-β
FKBP10 siRNA
TGF-β
FKBP10 siRNA
TGF-β
FKBP10 siRNA
Figure 6. FK506-binding protein 10 (FKBP10) is up-regulated by transforming growth factor (TGF)-b1 in primary human lung fibroblasts (phLF), and
knockdown of FKBP10 attenuates synthesis of collagen I, collagen V, and a-smooth muscle actin (a-SMA). (A) Western blot analysis of phLF
treated with increasing concentrations of TGF-b1 (0.1, 0.2, 1.0, 2.0, and 5.0 ng/ml) shows up-regulation of FKBP10 at 48 hours in the presence of
1.0 ng/ml and higher TGF-b1 concentrations. Efficacy of TGF-b1 treatment was confirmed by monitoring phosphorylation of mothers against
decapentaplegic homolog 3 (SMAD3, depicted as pSMAD3) in comparison with total SMAD3 levels (SMAD3). (B) 2.0 ng/ml TGF-b1 significantly increased
FKBP10 in phLF after 48 h, as quantified by densitometric analysis from Western blot analysis (cf. Figure 7C for representative Western blot, lanes
with scrambled [2] small interfering RNA [siRNA] only). The effect of the knockdown was always significant (P, 0.01 or P, 0.001) but is not specified in
the interest of clarity. (C) FKBP10 knockdown effects in phLF in combination with 24 and 48 hours of TGF-b1 treatment (2.0 ng/ml). A representative
Western blot analysis for detection of FKBP10, collagen I, collagen V, fibronectin, and a-SMA is shown. (D) Densitometric quantification of collagen I,
collagen V, fibronectin, and a-SMA protein levels. b-actin (ACTB) was used as loading control. Scrambled siRNA was used as control. Data are
based on eight completely independent experiments and are given as mean6 SEM. Statistical analysis for comparison of FKBP10 siRNA vs. scrambled
siRNA control was performed by paired two-tailed t test. *P, 0.05, **P, 0.01. The well-known effect of TGF-b1 on these proteins was mostly significant
but is not specified in the interest of clarity. ctrl = control.
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Here, we demonstrate that FKBP10
localized mainly to the ER in phLF
(Figure 5). No colocalization was observed
with the Golgi-specific protein GOLGA1
(29), indicating that FKBP10 is not
associated with transport processes across
the trans-Golgi network to the extracellular
space. This suggests that FKBP10 mainly
functions as an ER-resident chaperone
and/or foldase in phLF, which agrees with
previous studies in chondroblasts and
embryonic fibroblasts (19, 27).
As there is evidence that ER stress
contributes to IPF pathology (30, 31), we
assessed whether FKBP10 is induced by ER
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Figure 7. Transforming growth factor (TGF)-b1 induces FK506-binding protein 10 (FKBP10) expression, and knockdown of FKBP10 in primary human lung
fibroblasts (phLF) significantly decreases expression of collagen a-1(I) chain (COL1A1), collagen a-1(V) chain (COL5A1), and plasminogen activator inhibitor 1 (PAI1) on
the transcriptional level independent of the canonical TGF-b signaling pathway. (A) Quantitative reverse transcriptase–polymerase chain reaction analysis of transcript
levels of COL1A1 and COL5A1 (encoding the a1-chain of collagen I and V, respectively) and PAI1 as a representative TGF-b1–transduced gene after FKBP10
knockdown in combination with 24 and 48 hours of TGF-b1 treatment (2.0 ng/ml). Data are depicted as mean6 SEM from eight independent experiments, and
a paired two-tailed t test was used for statistical analysis for comparison of FKBP10 small interfering RNA (siRNA) vs. scrambled siRNA control. The well-known
effect of TGF-b1 on these transcripts was always highly significant (P,0.01 or P,0.001) but is not specified in the interest of clarity. Hypoxanthine-guanine
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FKBP10 knockdown showed no effect on canonical TGF-b signaling (n=3). (D) Western blot analysis (n =3) demonstrated that FKBP10 knockdown did not affect
levels of total and phosphorylated SMAD3. b-actin (ACTB) was used as loading control. For quantification of these data, see Figure E3 in the online supplement.
*P,0.05, **P,0.01, ***P,0.001. ctrl = control.
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stress as a possible explanation for its
increased expression in IPF. Interestingly,
we observed a drastic decrease in FKBP10
levels (band at 70 kD; cf. Figure E1A) in
response to tunicamycin, an inhibitor of
N-protein glycosylation (32). This decrease
was accompanied by the appearance of
a lower band at the height of the predicted
size of the unmodified protein (65 kD; cf.
Figure E1A), in line with the previous
identification of FKBP10 as an N-glycosylated
protein (33). This is in agreement with
a previous study showing that FKBP10 is
degraded by the proteasome in response to
ER stress (34). As the observed decrease of
FKBP10 might reflect deglycosylation of the
protein rather than an overall decrease in
expression levels, a mechanistically
independent ER stress inducer, thapsigargin,
was used to confirm FKBP10 down-
regulation in ER stress (Figure E1B). Hence, it
is unlikely that the unfolded protein response
contributes to FKBP10 up-regulation in IPF.
In contrast, TGF-b1 significantly
induced FKBP10 expression in phLF on the
mRNA and protein level (cf. Figure E2,
Figure 6B). This effect has previously only
been observed in fetal lung fibroblasts (26)
and implies that adult IPF phLF have
retained the capacity to up-regulate
FKBP10 under fibrotic conditions,
supporting the use of this cell culture
system for the functional analysis of
FKBP10 in vitro. In agreement with
a collagen chaperone function, inhibition
of FKBP10 by an siRNA-mediated
approach in this model resulted in
a consistent decrease of collagen I and
collagen V protein levels (cf. Figure 6C and
6D) as well as in decreased secreted
collagen (Figure 8). In line with our results,
deficiency of FKBP10 in osteogenesis
imperfecta has been shown to attenuate
collagen secretion and, moreover,
decrease the extent of lysyl hydroxylation
and extracellular collagen cross-linking and
increase protease sensitivity of extracellular
collagen I in dermal fibroblasts from patients
with osteogenesis imperfecta (15, 17, 18).
Surprisingly, loss of FKBP10 affected
collagen levels not only on protein but also on
transcript levels (Figure 7A). This is
unexpected, as FKBP10—as a chaperone and
peptidyl-prolyl isomerase—is mainly ascribed
a post-transcriptional role in procollagen I
processing (11, 14, 15, 17, 18). Interestingly,
loss of FKBP10 also attenuated the expression
of the TGF-b–responsive genes PAI1 and
a-SMA (Figures 6D and 7A). However, this
was not due to inhibition of the canonical
TGF-b signaling pathway (Figure 7B–7D).
Hence, it appears that FKBP10 exerts
a previously unappreciated function in signal
transduction processes for the transcriptional
regulation of profibrotic genes. Nevertheless,
the data also show an increase in TGF-
b–induced collagen expression and secretion,
even in the context of FKBP10 knockdown,
indicating that alternative, FKBP10-
independent, profibrotic mechanisms
contribute to overall ECM deposition.
Importantly, the effects of FKBP10
knockdown on TGF-b–induced collagen
secretion in phLF were comparable to
those of submicromolar concentrations of
nintedanib (Figures 9A and 9B). In
contrast, we did not observe any effect of
pirfenidone in this context. Previous
studies in human lung fibroblasts and A549
cells have shown moderate reduction of
collagen I expression only at concentrations
higher than those used in this study (1.0
mM vs. 1.6 and 2.7 mM pirfenidone,
respectively [35, 36]). The effect of
pirfenidone on TGF-b–induced collagen
secretion in vitro has, to our knowledge,
only been studied in trabecular meshwork
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Figure 8. Knockdown of FK506-binding protein 10 (FKBP10) attenuates collagen secretion. (A)
Western blot analysis of secreted collagen I. Collagen I was precipitated from cell culture supernatant
after FKBP10 knockdown in combination with 24 and 48 hours of transforming growth factor
(TGF)-b1 treatment (2.0 ng/ml) and analyzed by Western blot analysis. (B) Densitometric analysis of
secreted collagen I as detected in A. Data shown are based on seven independent experiments and
given as mean6 SEM. (C) Results of a Sircol assay for assessment of total secreted collagen in cell
culture supernatant after FKBP10 knockdown in combination with 24 and 48 hours of TGF-b1
treatment. Data shown are based on eight independent experiments and given as mean6 SEM.
Statistical analysis was performed using paired two-tailed t test for comparison of FKBP10 siRNA vs.
scrambled siRNA control. ctrl = control; siRNA = small interfering RNA. *P , 0.05, **P , 0.01.
ORIGINAL ARTICLE
464 American Journal of Respiratory and Critical Care Medicine Volume 192 Number 4 | August 15 2015
cells, where collagen secretion was
significantly reduced at a concentration of
2.5 mM (37). These concentrations are
hardly physiologically relevant, indicating
that the well-known antifibrotic effects of
pirfenidone in vivo (38) differ substantially
in underlying mechanisms or involve
metabolic activation.
The ability to bind the
immunosuppressive drug FK506
(tacrolimus) via at least one peptidyl-prolyl
isomerase domain is characteristic for all
FKBPs, including FKBP10 (11, 39).
Interestingly, immunosuppressive
peptidyl-prolyl isomerase inhibitors like
FK506 have been ascribed potent
antifibrotic effects in lung fibrosis
(40–43). FK506 suppresses collagen
synthesis and expression of the TGF-b1
receptor in dermal and lung fibroblasts,
but the underlying mechanisms are
largely unclear (41, 44, 45). Our
findings put forward the possibility that
inhibition of FKBP10 might contribute
to the antifibrotic effects of FK506.
In conclusion, we show that
FKBP10 is overexpressed in bleomycin-
induced lung fibrosis and IPF. Up-
regulation of FKBP10 expression is at least
partly mediated by TGF-b1. Loss of
FKBP10 in phLF derived from patients
with IPF or control patients attenuated
ECM protein expression and secretion
and suppressed fibroblast-to-
myofibroblast differentiation/activation.
Although FKBP10 has been suggested to
be important for normal lung
development, with little expression in
normal adult tissues, its expression
appears to be reactivated during lung
fibrosis (26, 27). Considering the impact
of FKBP10 on collagen cross-linking (15,
17, 18) and the effects described herein
on collagen secretion, FKBP10 might
provide a very specific and effective drug
target for treatment of IPF. n
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FK506-binding protein 10 (FKBP10)
regulates lung fibroblast migration via
collagen VI synthesis
Larissa Knüppel1,2, Katharina Heinzelmann1,2, Michael Lindner3, Rudolf Hatz3,4, Jürgen Behr3,5,
Oliver Eickelberg1,2,6 and Claudia A. Staab-Weijnitz1,2*
Abstract
Background: In idiopathic pulmonary fibrosis (IPF), fibroblasts gain a more migratory phenotype and excessively
secrete extracellular matrix (ECM), ultimately leading to alveolar scarring and progressive dyspnea. Here, we
analyzed the effects of deficiency of FK506-binding protein 10 (FKBP10), a potential IPF drug target, on primary
human lung fibroblast (phLF) adhesion and migration.
Methods: Using siRNA, FKBP10 expression was inhibited in phLF in absence or presence of 2ng/ml transforming
growth factor-β1 (TGF-β1) and 0.1mM 2-phosphoascorbate. Effects on cell adhesion and migration were monitored
by an immunofluorescence (IF)-based attachment assay, a conventional scratch assay, and single cell tracking by
time-lapse microscopy. Effects on expression of key players in adhesion dynamics and migration were analyzed by
qPCR and Western Blot. Colocalization was evaluated by IF microscopy and by proximity ligation assays.
Results: FKBP10 knockdown significantly attenuated adhesion and migration of phLF. Expression of collagen VI was
decreased, while expression of key components of the focal adhesion complex was mostly upregulated. The effects
on migration were 2-phosphoascorbate-dependent, suggesting collagen synthesis as the underlying mechanism.
FKBP10 colocalized with collagen VI and coating culture dishes with collagen VI, and to a lesser extent with
collagen I, abolished the effect of FKBP10 deficiency on migration.
Conclusions: These findings show, to our knowledge for the first time, that FKBP10 interacts with collagen VI and
that deficiency of FKBP10 reduces phLF migration mainly by downregulation of collagen VI synthesis. The results
strengthen FKBP10 as an important intracellular regulator of ECM remodeling and support the concept of FKBP10
as drug target in IPF.
Keywords: FKBP10, FKBP65, migration, focal adhesion, collagen VI, lung fibrosis, fibroblast, fibulin
Background
Patients suffering from idiopathic pulmonary fibrosis (IPF),
a highly progressive interstitial lung disease, have a median
survival prognosis of 2-5 years after diagnosis [1]. The
pathogenic processes are not completely understood. It is
currently believed that the fibrotic response is caused by re-
peated micro-injuries of the respiratory epithelium [2]
which leads to the release of profibrotic mediators like
transforming growth factor β1 (TGF-β1), followed by myo-
fibroblast differentiation, increased fibroblast migration,
and, ultimately, excessive deposition of extracellular matrix
(ECM) in the alveolar region [3–6]. More recent evidence
suggests that the composition of the ECM strongly affects
fibroblast phenotypes and therefore plays a crucial role in
disease progression [4, 7, 8].
Aberrant fibroblast adhesion and migration are com-
mon features of fibrosis [9–11] and targeting fibroblast
migration, e.g. by inhibition of focal adhesion kinase
(FAK) or of integrins, has been proposed as a treatment
strategy [12, 13]. For instance, myofibroblasts possess an
increased ability to adhere to the ECM, which is
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mediated by focal adhesions (FA) attaching the actin
cytoskeleton to the matrix [14]. Cell attachment to the
ECM via clustering of integrins leads to the recruitment
of numerous FA proteins with adapter, structural, and
enzymatic functions [15, 16]. For instance, structural
proteins like talin, vinculin and α-actinin facilitate the
connection between integrins and actin fibers and pro-
vide the basis for the transmission of mechanical forces
between cell and ECM [17]. To enable cell migration,
turnover of FA is necessary. Several factors are involved
in FA disassembly, like actin dynamics, FAK and Src
phosphorylation, and ERK/MAP kinase-mediated activa-
tion of calpain-2, a calcium-dependent protease [15].
Finally, migration is strongly influenced by topology
and composition of the ECM including integrin ligands
like collagen, fibronectin (FN), and laminin [7]. Collagen
type VI appears to play a particularly important role in
this context, as several studies indicate a central, albeit
context-dependent and tissue-specific role of collagen VI
for migration and adhesion [18–20].
FK506-binding protein 10 (FKBP10, also termed
FKBP65), a member of the family of immunophilins, is
an endoplasmic reticulum (ER) -resident peptidyl prolyl
isomerase and a collagen I chaperone [21]. We have pre-
viously reported upregulation of FKBP10 in experimen-
tal lung fibrosis and IPF, where it is mainly expressed by
(myo)fibroblasts [22]. Deficiency of FKBP10 by siRNA-
mediated knockdown in primary human lung fibroblasts
(phLF) reduced the expression of profibrotic markers
like α-smooth muscle actin (α-SMA), FN and collagen I,
and suppressed collagen secretion [22].
As properties of the ECM play an important role in
adhesion dynamics and FKBP10 has been identified pre-
viously as a regulator of collagen biosynthesis in phLF,
the aim of this study was to assess the effect of FKBP10
deficiency on adhesion and migration in phLF. To
elucidate the underlying mechanisms, we analyzed the
effect of siRNA-mediated knockdown of FKBP10 on
intracellular and membrane-spanning components of
the FA complex, on regulatory events of FA turnover, on
proteins involved in actin dynamics, and, finally, on a se-
lection of ECM proteins with important emerging func-
tions in migration.
Methods
Material
Primers were obtained from MWG Eurofins (Ebersberg,
Germany) and are shown in Table 1. Table 2 contains
used primary antibodies. HRP-linked and fluorescent la-
beled secondary antibodies were purchased from GE
Healthcare Life Sciences (Freiburg, Germany).
Statistical Analysis
Statistical analysis was performed in GraphPadPrism 5
(GraphPad Software, San Diego, CA, USA). Results are
shown as mean ± SEM. Paired t-test was used for statis-
tical analysis. Notably, analysis using a Wilcoxon signed
rank test yielded very similar results except for the
scratch assays shown in Fig. 5a where results just failed
significance (not shown). Significance is indicated as fol-
lows: *p<0.05, **p<0.01, ***p<0.001.
Human Lung Material, Isolation and Culture of phLF
Primary human lung fibroblasts (phLF) were isolated
from human lung tissue and derived from in total eight
different patients. The tissue derived from human lung
explant material of IPF patients or histologically normal
regions adjacent to resected lung tumors was obtained
from the BioArchive CPC-M for lung diseases at the
Comprehensive Pneumology Center (CPC Munich,
Germany). The study was approved by the local ethics
committee of the Ludwig-Maximilians University of
Table 1 Primer table for Real-Time Quantitative Reverse-Transcriptase PCR (qRT-PCR). Primers were synthesized by MWG Eurofins
(Ebersberg, Germany).
Target Species Forward primer (5′-3′) Reverse primer (5′-3′)
CAPNS1 human GACGCTACTCAGATGAAAGT TCTTTGTCAAGAGATTTGAAG
CAV1 human TCACTGTGACGAAATACTG CGTAGATGGAATAGACACG
COL6A1 human GACGCACTCAAAAGCA ATCAGGTACTTATTCTCCTTCA
COL6A2 human AGAAAGGAGAGCCTGCGGAT AGGTCTCCCTCACGTAGGTC
COL6A3 human CTCTACCGAGCCCAGGTGTT ATGAGGGTGCGAACGTACTG
CORO1C human GTTAACAAATGTGAGATTGC TGGAAAAGGTCAGACTTC
DHX8 human TGACCCAGAGAAGTGGGAGA ATCTCAAGGTCCTCATCTTCTTCA
ERK1 human TTCGAACATCAGACCTACT AGGTCCTGCACAATGTAG
FBLN1C human GCCCTGAGAACTACCG GAGAGGTGGTAGTAGGTTATTC
FKBP10 human CGACACCAGCTACAGTAAG TAATCTTCCTTCTCTCTCCA
ITGB1 human TTACAAGGAGCTGAAAAACT AAAATGACTTCTGAGGAAAG
TLN1 human GCTCTTTCTGTCAGATGAT CATAGTGTCCCCATTTC
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Munich, Germany, and all participants gave written in-
formed consent. Isolation and culture of phLF was per-
formed as described previously [22, 23]. Notably, in
previous studies, we have never seen consistent expres-
sion differences between control and IPF fibroblasts, nei-
ther in terms of basal and TGF-β1-induced gene
expression of collagens and collagen biosynthetic en-
zymes, nor in terms of collagen secretion [22, 23].
Transfection of phLF and TGF-β1 Treatment
Cells were seeded at a density of 20.000–25.000 cells/
cm2. Reverse transfection was carried out with human
small interfering RNA of FKBP10 (siRNA) (s34171; Life
Technologies, Carlsbad, CA) or negative control siRNA.
Twenty-four hours later starvation for another 24 hours
in Dulbecco’s modified Eagle medium/F-12 including
0.5% fetal bovine serum and 0.1 mM 2-phospho-L-as-
corbic acid was performed. Then, cells were treated with
2 ng/ml TGF-β1 (R&D Systems, Minneapolis, MN) in
starvation medium for another 24 - 48 h, followed by
harvesting for RNA and protein analysis. Unless stated
otherwise, all data is derived from eight independent
knockdown experiments in at least three and maximally
in eight different human primary fibroblast lines. For
fibroblast lines that had been used for more than one
knockdown experiment in different passages, typically a
mean was formed for these experiments prior to statistical
analysis to avoid overrepresentation of one biological
replicate in the data.
RNA Isolation and Real-Time Quantitative Reverse-
Transcriptase PCR (qRT-PCR) Analysis
RNA isolation and qRT-PCR analysis were performed as
described previously [22, 23].
Protein Isolation and Western Blot analysis
Protein isolation and Western Blot analysis were per-
formed as described previously [22, 23].
Table 2 Primary antibodies used in Western Blot analysis, Immunofluorescence and Proximity Ligation Assays
Target Abbreviation Antibody Provider Application
β-actin ACTB HRP-conjugated anti-ACTB antibody Sigma Aldrich, St. Louis, USA WB
Calpain-4 CAPNS1 mouse monoclonal anti-Calpain-4 Abnova, Taipei City, Taiwan WB, IF, PLA
Caveolin-1 CAV1 rabbit monoclonal anti-Caveolin-1 antibody Cell Signaling, Boston, USA WB
Collagen VI α1 COL6A1 mouse monoclonal anti-Collagen VI A1 antibody Santa Cruz, Dallas, USA WB, IF, PLA
Collagen VI α3 COL6A3 mouse monoclonal anti-Collagen VI A3 antibody Santa Cruz, Dallas, USA IF, PLA
Coronin 1C CORO1C mouse monoclonal anti-CORO1C antibody Santa Cruz, Dallas, USA WB, IF, PLA
Extracellular Signaling Related
Kinase 1
ERK1 mouse monoclonal anti-ERK1 antibody BD Biosciences, New Jersey, USA WB
ER protein 57 (Protein
disulfide-isomerase A3)
ERp57 mouse monoclonal anti-ERp57 Abcam, Cambridge, UK PLA
Fibulin-1 FBLN1 mouse monoclonal anti-FBLN1 antibody Santa Cruz, Dallas, USA WB, IF, PLA
FK506-binding protein 10 FKBP10 rabbit polyclonal anti-FKBP10 antibody ATLAS, Stockholm, Sweden WB, IF, PLA
Focal Adhesion Kinase FAK rabbit polyclonal anti-FAK antibody Santa Cruz, Dallas, USA WB
Golgin97 CDF4 mouse monoclonal anti-Golgin97 antibody Invitrogen, Carlsbad, USA PLA
mouse IgG (neg. ctrl) mouse IgG mouse IgG1κ isotype control eBioscience, San Diego, USA PLA
Integrin-β1 ITGB1 mouse monoclonal anti-ITGB1 antibody Abcam, Cambridge, UK WB
Phosphorylated Extracellular
Signaling Related Kinase 1/2
p-ERK1/2 rabbit monoclonal anti-pERK1/2 (Thr202/Tyr204) Cell Signaling, Boston, USA WB
Phosphorylated Focal
Adhesion Kinase
p-FAK Y397 rabbit monoclonal anti-pFAK (Tyr397) Cell Signaling, Boston, USA WB
Phosphorylated Focal
Adhesion Kinase
p-FAK Y566/577 rabbit monoclonal anti-pFAK (Tyr576/Tyr577) Biomol, Hamburg, Germany WB
Phosphorylated SRC
Proto-Oncogene, Non-
Receptor Tyrosine Kinase
p-Src rabbit polyclonal anti-pSrc (Tyr416) Cell Signaling, Boston, USA WB
SRC Proto-Oncogene, Non-
Receptor Tyrosine Kinase
Src mouse monoclonal anti-Src Cell Signaling, Boston, USA WB
Talin 1 TLN1 mouse monoclonal anti-TLN1 Sigma Aldrich, Dt. Louis, USA WB, IF, PLA
Secondary HRP-linked antibodies and secondary antibodies (Alexa Fluor 488 goat anti-mouse IgG, Alexa Fluor 568 goat anti-rabbit IgG) for IF were purchased from
GE Healthcare Life Sciences (Freiburg, Germany). 4',6-Diamidino-2-phenylindole (DAPI) was used for nuclear staining (Sigma-Aldrich, St. Louis, USA)
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Cell Fixation and Immunofluorescent Stainings
Cells were seeded on FN-coated coverslips (6 μg/mL,
Sigma-Aldrich, St. Louis, USA), followed by serum star-
vation and TGF-β1 treatment for 48h as described
above. The fixation method was chosen accordingly to
the used antibodies. For methanol fixation, cells were
washed once in 1x phosphate-buffered saline (PBS),
followed by fixation with 100% methanol for 2 minutes
on ice and three additional washing steps with 1x PBS to
remove the residual methanol.
For para-formaldehyde (PFA) fixation, cells were
washed once with 1x PBS and 4% PFA was added to the
cells followed by incubation at room temperature for 20
minutes. Residual PFA was removed by three washing
steps with 1x PBS. Staining of the cover slips was per-
formed as described before [22]. Immunofluorescence
(IF) was examined by acquiring z-stack images with an
Axio Imager M2 Microscope (Carl Zeiss, Jena, Germany)
and analysed by AxioVision 4.8 software.
Proximity Ligation Assay (PLA)
Cells were seeded, treated with TGF-β1 for 48h, and
methanol-fixed as described above. The Duolink® PLA Kit
(Sigma Aldrich, St. Louis, USA) was used and carried out
according to the manufacturer’s protocol. Interaction of
FKBP10 with target proteins was visualized using an Axio
Imager M2 Microscope (Carl Zeiss, Jena, Germany).
Cell Adhesion Assay
For analysis of cell attachment in FKBP10-deficient
phLF, cells were seeded and treated as described above.
After 48h of TGF-β1 treatment and 96h of siRNA
knockdown, cells were trypsinized and counted. Per con-
dition, four replicates with 100.000 cells per 48-well
were seeded and incubated for 1 hour at 37°C, 5% CO2.
Wells were carefully washed once with 1 x PBS to re-
move non-adherent cells and attached cells were fixed
with 4% PFA as described before. Cells were stained with
4′,6-Diamidin-2-phenylindol (DAPI) and Phalloidin, la-
beled with Alexa Fluor 568 (Invitrogen) followed by im-
aging using an LSM T-PMT microscope (Carl Zeiss,
Jena, Germany). Attached cells were counted using
IMARIS Software 9.0. Results were normalized to non-
treated control and visualized as percentage of attached
cells.
Scratch Assay
Cells were seeded at a density of 35.000 cells/cm2 and
siRNA-mediated knockdown of FKBP10 was performed
as described above. To reach 100% confluency, cells
were grown for 48h followed by starvation for 24h. A
scratch was executed using a 1000 μL pipette tip and
TGF-β1 was added. Images were taken at time point 0h
using an inverse microscope (Primovert, Carl Zeiss, Jena,
Germany) and the section was marked by a black dot.
After 24h, additional images were taken to compare
wound closure between control and FKBP10 deficient
cells. Results are given in percent of wound closure nor-
malized to untreated control.
Single Cell Migration Assay Using Time Lapse Microscopy
Cells were seeded at a density of 5.500 cells/cm2 on
uncoated, collagen I-coated (~50 μg/mL, Sigma-Aldrich,
St. Louis, USA), or collagen VI-coated (10 μg/mL,
Abcam, Cambridge, UK) wells. Knockdown by siRNA of
FKBP10 was performed as described above. After 24h,
cells were serum-starved for another 24h followed by
TGF-β1 treatment (2 ng/mL) for 24h. Movies were gen-
erated over a period of 12h - 24h using Axio Observer
Z1 microscope equipped with an AxioCam camera (Carl
Zeiss, Jena, Germany) and images were taken in 20 min
intervals. Single cell movement was analyzed using the
cell tracking tool of the AxioVision 4.8 software (Carl
Zeiss, Jena, Germany).
Results
Deficiency of FKBP10 attenuates migration and adhesion
of primary human lung fibroblasts
SiRNA-mediated knockdown of FKBP10 expression in
phLF was highly efficient on both protein and mRNA
level (Fig. 1a, b, knockdown efficiency 86% ± 5%).
Wound closure in a conventional scratch assay was sig-
nificantly reduced in FKBP10-deficient cells compared
to control in absence of TGF-β1. A similar trend was
observed in presence of TGF-β1, which just failed sig-
nificance (Fig. 1c, d). These results were confirmed with
an independent and more accurate method, namely a
single cell migration assay using time-lapse microscopy
to track individual cells. In this assay, FKBP10-deficient
cells showed a highly significant reduction of mean vel-
ocity both in absence and presence of TGF-β1 (Fig. 1e).
Next, we investigated the effect of siRNA-mediated
knockdown of FKBP10 on adhesion of phLF using an
IF-based attachment assay. In presence of TGF-β1,
FKBP10 deficiency significantly reduced the ability of
phLF to adhere to the cell culture dish surface (Fig. 1f ).
While TGF-β1 had no significant effect on migration,
neither in the scratch nor in the single cell tracking
assay, TGF-β1 significantly increased fibroblast adhesion.
Deficiency of FKBP10 upregulates expression of key
molecules of adhesion and migration in primary human
lung fibroblasts, but does not alter the activation of focal
adhesion kinase and downstream pathways
To gain a better understanding of the effect of FKBP10
deficiency on adhesion and migration, we analyzed sev-
eral selected proteins with key functions in these pro-
cesses. In terms of altered gene expression of focal
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adhesion and ECM components, we only observed mar-
ginal differences between fibroblasts isolated from nor-
mal histology control or from IPF lung tissue and
therefore decided to pool the data. Deficiency of FKBP10
in phLF led to induction of the focal adhesion compo-
nent talin-1 (TLN1) on protein and mRNA level in ab-
sence and presence of TGF- β1 (Fig. 2a, b). Next, we
investigated the effect of FKBP10 knockdown on
calpain-4 (CAPNS1), the small regulatory subunit of
calpain-1 and calpain-2, which is indispensable for for-
mation and strengthening of adhesions and for mechan-
osensing during fibroblast migration [24]. Similar to
TLN1, CAPNS1 expression was significantly upregulated
in absence and presence of TGF-β1 on transcript level
(Fig. 2c, d); this effect, however, translated to the protein
level only in absence of TGF-β1. Moreover, FKBP10
a b
c d
e f
Fig. 1 Knockdown of FKBP10 reduces migration and adhesion of phLF. a Western Blot analysis of phLF treated with scrambled siRNA as control
(sc) or FKBP10 siRNA (kd) and 2-phosphoascorbate (0.1 mM) in absence and presence of TGF-β1 (2 ng/mL) for 48h. Densitometric analysis and
representative blots show the effect of FKBP10 knockdown on the expression of FKBP10 relative to β-actin as loading control (ACTB). b Quantitative
reverse transcriptase-polymerase chain reaction analysis of phLF treated with sc siRNA as control or FKBP10 siRNA (kd) and 2- phosphoascorbate
(0.1 mM) in absence and presence of TGF-β1 (2 ng/mL) for 48h. Transcript levels are shown as -ΔCt values. DEAH (Asp-Glu-Ala-His) Box
Polypeptide 8 (DHX8) was used as endogenous control. Data (a, b) is based on eight independent experiments. c Representative images
of a scratch assay of phLF treated with sc siRNA as control or FKBP10 and 2- phosphoascorbate (0.1 mM) in absence or presence of TGF-
β1 (2 ng/mL). Images were taken at 0h and after 24h. d Analysis of open wound areas as shown in (c) normalized to controls at 0h
(100%), given in % of the remaining wound area. Data is based on four independent experiments. e SCM assay of phLF treated with sc
siRNA as control or FKBP10 siRNA and 2- phosphoascorbate (0.1 mM) in absence and presence of TGF-β1 (2 ng/mL). Cells were tracked
over a period of 12h - 24h. Results of five independent experiments are shown as mean velocity of around 80 tracked cells per condition.
f Cell attachment assay of phLF treated with sc siRNA as control or FKBP10 siRNA in absence or presence of TGF-β1 (2 ng/mL) for 48h.
Results originate from six independent experiments and are visualized as percentage of cell adhesion normalized to non TGF-β1-
treated cells. Statistical significance between control and FKBP10 kd is indicated by horizontal brackets and asterisks
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knockdown also increased protein levels of the trans-
membrane collagen receptor integrin-β1 (ITGB1), par-
ticularly in presence of TGF-β1 (Fig. 2e), while
transcript levels were not significantly changed (Fig. 2f ).
Finally, two modulators of cytoskeleton dynamics,
caveolin-1 (CAV1) and coronin-1C (CORO1C), were
regulated in opposite directions: Whereas CAV1 expres-
sion (protein and mRNA) was downregulated upon
FKBP10 knockdown in presence of TGF-β1 (Fig. 2g, h),
CORO1C protein levels were upregulated (Fig. 2i, j).
FAK activation by either integrins or growth factors
leads to autophosphorylation of Tyr 397 in FAK,
creating a motif which results in binding and conform-
ational activation of proto-oncogene tyrosine-protein
kinase Src. Active Src triggers further FAK phosphor-
ylation on Tyr sites like Tyr 576/577, starting the ras-
raf-MEK-ERK signal transduction cascade which is
implicated in many processes including cell adhesion
and migration. MEK1/2 catalyzes ERK1/2 phosphoryl-
ation on specific Tyr and Thr residues essential for
enzyme activity [25, 26].
Deficiency of FKBP10 slightly upregulated total FAK
levels (Fig. 3a); however, there was no significant effect
on the phosphorylation on Tyr 397 or Tyr 576/577 of
a
b
c
d
g
h j
i
e
f
Fig. 2 FKBP10 deficiency alters the expression of molecules implicated in adhesion and migration. a, c, e, g, i Western Blot analysis of phLF
treated with scrambled siRNA as control (sc) or FKBP10 siRNA (kd) and 2- phosphoascorbate (0.1 mM) in absence and presence of TGF-β1 (2 ng/mL)
for 48h. Densitometric analysis and representative blots show the effect of FKBP10 kd on the expression of talin-1 (TLN1) (a), calpain-4 (CAPNS1) (c),
integrin β1 (ITGB1) (e), caveolin-1 (CAV1) (g) and coronin 1C (CORO1C) (i) relative to β-actin as loading control (ACTB). b, d, f, h, j Quantitative reverse
transcriptase-polymerase chain reaction analysis of phLF treated with scrambled siRNA as control (sc) or FKBP10 siRNA (kd) and 2- phosphoascorbate
(0.1 mM) in absence and presence of TGF-β1 (2 ng/mL) for 48h. Transcript levels are presented as -ΔCt values showing the effect of siRNA mediated
kd of FKBP10 on talin-1 (TLN1) (b), calpain-4 (CAPNS1) (d), integrin β1 (ITGB1) (f), caveolin-1 (CAV1) (h) and coronin 1C (CORO1C) (j). DEAH (Asp-Glu-
Ala-His) Box Polypeptide 8 (DHX8) was used as endogenous control. All data is based on eight (protein) or seven (mRNA) independent experiments.
Statistical significance between control and FKBP10 kd is indicated by horizontal brackets and asterisks
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FAK (Fig. 3b, c). Similarly, none of the assessed down-
stream signaling pathways appeared affected: Neither
levels of total Src and phospho-Src nor levels of total
ERK1 and phosphorylated ERK1/2 changed upon
FKBP10 knockdown (Fig. 3d-g).
FKBP10 interacts with type VI collagen and fibulin-1 and
regulates their expression
As changes in expression of focal adhesion complex
components and in events during FAK signaling did not
explain the observed attenuated migration upon FKBP10
knockdown, we reasoned that changes in ECM compos-
ition could be the main cause of reduced migration vel-
ocity. Besides the ECM proteins collagen I and FN,
which we reported to be downregulated upon FKBP10
knockdown previously [22], collagen VI and fibulin-1
also have been described to maintain important roles in
the process of cell migration [18, 27]. Here, we found
that collagen VI and fibulin-1 expression were regulated
in different directions in response to FKBP10 knock-
down. Collagen 6A1 was significantly reduced on protein
level in FKBP10 deficient phLF with and without TGF-
β1, whereas COL6A1 transcript was only reduced in
presence of TGF-β1 (Fig. 4a, b). Interestingly, mRNA
levels of COL6A2 and COL6A3 chains were not influ-
enced by FKBP10 deficiency (Fig. 4c, d). In contrast,
fibulin-1 protein expression was increased in response to
FKBP10 knockdown in absence and presence of TGF-
β1; transcript levels of FBLN1C were significantly upreg-
ulated under basal conditions upon FKBP10 knockdown
(Fig. 4e, f ).
Co-localization of FKBP10 with both, collagen VI
(COL6A1 and COL6A3) (Fig. 4g, h) and fibulin-1 (Fig. 4i)
was examined by IF stainings and PLA (Fig. 4j). Negative
a
b
c
d
e
f
g
Fig. 3 Neither FAK, Src, nor ERK1/2 activation is affected by FKBP10 kd. Western Blot analysis of phLF treated with scrambled siRNA as control (sc)
or FKBP10 siRNA (kd) and 2- phosphoascorbate (0.1 mM) in absence and presence of TGF-β1 (2 ng/mL) for 48h. Densitometric analysis and representative
blots show the effect of FKBP10 kd on the expression of FAK (a), Src (d) and ERK1 (f) relative to β-actin as loading control (ACTB). b, c Densitometric analysis
and representative blots showing the effect of FKBP10 kd on the phosphorylation of FAK (Y397) (b) and FAK (Y576/577) (c) relative to FAK. e, g
Densitometric analysis and representative blots showing the effect of FKBP10 kd on the phosphorylation of Src (Y416) (e) relative to Src
and pERK1/2 (T202/Y204) (g) relative to ERK1. All data is based on eight independent experiments. Statistical significance between control
and FKBP10 kd is indicated by horizontal brackets and asterisks
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Fig. 4 FKBP10 interacts with COL6A1 and FBLN1 and regulates their expression. a, e Western Blot analysis of phLF treated with scrambled siRNA
as control (sc) or FKBP10 siRNA (kd) and 2- phosphoascorbate (0.1 mM) in absence and presence of TGF-β1 (2 ng/mL) for 48h. Densitometric analysis
and representative blots showing the effect of FKBP10 kd on the expression of Collagen VI alpha1 (COL6A1) (a) and fibulin-1 (FBLN1) (e) relative to β-
actin as loading control (ACTB). b, c, d, f Quantitative reverse transcriptase-polymerase chain reaction analysis of phLF treated with sc siRNA as control
or FKBP10 siRNA and 2-phosphoascorbate (0.1 mM) in absence and presence of TGF-β1 (2 ng/mL) for 48h. Transcript levels are shown as -ΔCt values
of showing the effect of FKBP10 kd on collagen VI alpha 1 (COL6A1) (b), collagen VI alpha 2 (COL6A2) (c), collagen VI alpha 3 (COL6A3) (d) and
fibulin-1C (FBLN1C) (f). DEAH (Asp-Glu-Ala-His) Box Polypeptide 8 (DHX8) was used as endogenous control. All data is based on eight (protein)
or seven (mRNA) independent experiments. Statistical significance is indicated by horizontal brackets and asterisks. g-i Immunofluorescence staining of
FKBP10 (green) and COL6A1 (red) (g), COL6A3 (red) (h) and FBLN1 (red) (i). 4`, 6-diamidino-2-phenylindole (DAPI) staining is shown in blue. The region
of interest is indicated by a white square and enlarged in the picture below. White arrows specify examples for co-localization of FKBP10 with COL6A1,
COL6A3 or FBLN1. Stainings were taken as z-stack and the enlarged pictures show one focal plane from this z-stack. Representative images were
selected from three independent experiments. j Representative images of in situ localization of the interaction of FKBP10 and COL6A1,
COL6A3, FBLN1, mouse IgG1κ (negative control), Golgin97 (negative control) and ERp57 (positive control), assessed by proximity ligation
assay. Representative images were selected from three independent experiments, except for IgG negative control (n=1)
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controls (mouse IgG and Golgin97) did not show any
interaction with FKBP10. Endoplasmic Reticulum Protein
57 (ERp57), previously reported by IF to co-localize with
FKBP10 [22] was used as positive control and showed
proximity to FKBP10. Positive signals were also observed
for COL6A1, COL6A3 and FBLN1, indicating interaction
with or proximity to FKBP10.
The effects of FKBP10 deficiency on migration and
adhesion depend on 2-phosphoascorbate and are
abolished by coating cell culture dishes with collagen VI
Post-translational modifications (PTM) like proline and
lysine hydroxylation of collagens (including collagen VI)
are crucial steps in collagen biosynthesis and catalyzed
by ascorbate-dependent prolyl and lysyl hydroxylases
[28–30]. In contrast, FBLN1 biosynthesis is not
dependent on ascorbate [31]. Therefore, we reasoned
that exclusion of ascorbate from the culture medium
would give us a first indication whether decreased
biosynthesis of collagen or increased biosynthesis of
fibulin may underlie the observed effects of FKBP10
deficiency on migration and adhesion. Notably, in ab-
sence of 2-phosphoascorbate the effect of FKBP10 de-
ficiency in phLF on adhesion and migration was lost,
in comparison to the results in presence of 2-
phosphoascorbate (Fig. 5), pointing towards a
collagen-dependent mechanism.
As both collagen I and collagen VI are downregulated
upon FKBP10 deficiency [22], we coated dishes with ei-
ther collagen I or collagen VI and analyzed migration in
a single-cell migration approach. Notably, the effect of
FKBP10 deficiency in phLFs on migration was com-
pletely lost when culture dishes were coated with
collagen VI (Fig. 6b) when compared to uncoated dishes
a
b
Fig. 5 The inhibitory effect of FKBP10 deficiency on migration and adhesion is 2-phosphoascorbate dependent. a Analysis of open wound areas
in scratch assays of phLF treated with scrambled siRNA (sc) as control or FKBP10 siRNA (kd) in absence and presence of TGF-β1 (2 ng/mL) and 0.1
mM 2-phosphoascorbate. Images were taken at 0h and after 24h. Data is normalized to controls at 0h (100%), given in % of the remaining wound
area and based on four independent experiments. b Cell attachment assay of phLF treated with scrambled siRNA (sc) as control or FKBP10 siRNA
(kd) in absence or presence of TGF-β1 (2 ng/mL) and 2-phosphoascorbate (0.1 mM) for 48h. Results originate from six independent experiments
and are visualized as percentage of cell adhesion normalized to non TGF-β1 treated. Experiments without and with 2- phosphoascorbate were
performed in parallel
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(Fig. 6a). Some compensation was also visible in collagen
I-coated dishes, albeit not that pronounced (Fig. 6c).
Discussion
In this study we demonstrated that FKBP10 deficiency
inhibited phLF adhesion and migration. This effect could
neither be explained by changes in expression or activa-
tion of components of the FA complex, nor by changes
in FAK downstream signaling events, nor by changes in
regulators of actin dynamics. Instead, we found that the
effect of FKBP10 deficiency on migration and adhesion
depended on 2-phosphoascorbate, pointing towards a
central role of collagen biosynthesis in this context. Loss
of FKBP10 downregulated the expression of collagen VI,
a collagen type increasingly recognized as a central
player in migration, and coating culture dishes with col-
lagen VI completely abolished the effect of FKBP10 defi-
ciency on phLF migration.
Next to excessive ECM deposition by interstitial fibro-
blasts, aberrant fibroblast adhesion and increased migra-
tion are also important features of IPF [6, 9–11]. Here
we show that loss of the collagen chaperone FKBP10,
which we previously identified as potential IPF drug tar-
get due to its role in ECM synthesis and secretion [22],
inhibited wound closure and reduced the mean velocity
and adhesion capacity of phLF (Fig. 1). This observation
is in line with the very recent report by Liang et al.,
showing that siRNA-mediated knockdown of FKBP10
led to reduced migration in human hypertrophic scar fi-
broblasts [32]. Collectively, these studies are confirma-
tive of our concept of FKBP10 as potential drug target in
fibrotic disease.
We assessed fibroblast migration both in a conven-
tional scratch assay as well as by tracking individual cells
with videomicroscopy in time-lapse experiments, a more
accurate approach. Overall, both assays consistently
showed reduced migration under conditions of FKBP10
deficiency, even if the scratch assay results in presence
of TGF-β1 failed significance (p=0.06). We believe that
this minor discrepancy reflects the well-known disadvan-
tages of the scratch assay, most importantly variations in
gap width due to the manually applied and therefore
often uneven scratch, the fact that ECM substrate is
equally scraped off together with the cells, and also the
mechanical cell damage which may introduce artifacts.
These technical drawbacks may explain the greater vari-
ations observed in this assay, leading to results that just
fail significance.
Our finding that TGF-β1 did not affect fibroblast mi-
gration is in agreement with previous studies by others
[33–35]. Increased fibroblast adhesion in presence of
TGF-β1 may in part reflect increased expression of β1-
integrin (this work, cf. Fig. 2e, f, scr ctrl vs. scr TGF-β1,
p=0.0642) and/or β3-integrins [36].
Initially, we sought to assess the effect of FKBP10 defi-
ciency on several regulatory levels of FA turnover to elu-
cidate the mechanism underlying attenuated migration.
Cell migration is a complex cyclic process starting with
the extension of membrane protusions (lamellipodia) at
the leading edge followed by their adhesion to the ECM
and retraction of the cell tail [37]. During cell migration
assembly and disassembly of FA is dynamically regu-
lated. The process of cell attachment to the ECM is initi-
ated by clustering of integrins on the cell surface,
heterodimeric transmembrane receptors consisting of α
and β subunits. The intracellular domains of the clus-
tered integrins serve as a platform for FA protein re-
cruitment and ultimately link the ECM via FA to actin
stress fibers [38]. In this context, TLN1 mediates the ini-
tiation of FA assembly by interacting with the cytoplas-
mic domain of the integrin β subunit on the one hand
and with actin and actin-binding proteins on the other
[15]. Another initial event upon integrin clustering is ac-
tivation of FAK including autophosphorylation of Tyr
a b c
Fig. 6 Coating of dishes with collagen VI abolishes the inhibitory effect of FKBP10 knockdown on migration. SCM assay of phLF treated with
scrambled siRNA as control (sc) or FKBP10 siRNA (kd) and 2- phosphoascorbate (0.1 mM) in absence and presence of TGF-β1 (2 ng/mL). Cells
were tracked over a period of 12h -24h. Results of three independent experiments are shown as mean velocity of around 80 tracked cells per
condition. Effect of collagen VI coated dishes on mean velocity of phLF is shown in (b) and of collagen I coated dishes in (c) compared to
uncoated dishes for control (a). Statistical significance between control and FKBP10 kd is indicated by horizontal brackets and asterisks
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397 and Src-mediated phosphorylation of additional
tyrosine residues within FAK (e.g. Y 566 and 577), which
are essential for full FAK activity. Active FAK interacts
with multiple signalling molecules including Grb7, PI3K,
paxillin, MLCK and ERK, activating signalling pathways
which result in protrusion extension, increased FA turn-
over, and therefore, ultimately, in increased cell motility
[15, 39–42]. The protease calpain 2, a heterodimer con-
sisting of a catalytic subunit and a regulatory subunit
(calpain-4, CAPNS1) plays a central role in this context
as it, when recruited by FAK and activated by ERK/MAP
kinase, mediates amongst others proteolysis of TLN1
and FAK, considered the rate-limiting step in FA turn-
over [15, 38, 39, 43, 44]. Finally, directional cell migra-
tion is strongly dependent on polarized actin dynamics.
Rho-like GTPases like RhoA and Rac1 control cytoskel-
eton contractility, polymerization, and protrusion. The
integral membrane protein caveolin-1 (Cav-1), activated
by small kinases like Src, is a central regulator of Rho-
like GTPase signaling in this context [45, 46]. Another
regulator of actin filament turnover in the lamellipodia
during cell migration is the actin binding protein coro-
nin 1C (CORO1C) [47].
FKBP10 deficiency led to several significant changes in
expression of FA components on all levels assessed, i.e.
upregulation of ITGB1, TLN1, CAPNS1, FAK, CORO1C
and downregulation of CAV1 (Fig. 2). Upregulation of
ITGB1 may associate with reduced FA turnover and
slow migration [48–50] but impaired migration and ad-
hesion has also been reported as a result of ITGB1 defi-
ciency [51]. Collectively, these findings suggest that
manipulation of ITGB1 protein levels in general is un-
favorable to cell motility, regardless of direction of regu-
lation. As ITGB1 functions as an adapter protein
between the ECM and intracellular FA complexes, it is
conceivable that its expression levels must be tightly reg-
ulated to allow for functional intermolecular interactions
between different interacting partners.
The same may apply to TLN1, an adapter protein link-
ing the cytoskeleton to ITGB1, where reports in the lit-
erature are also seemingly controversial: Upregulation of
TLN1, but also suppression of TLN1 has been reported
to reduce migration and adhesion [52–54]. Interestingly,
downregulation of TLN1 has also been associated with
increased migration [52, 55], which is in support of its
function as a regulator of FA turnover together with its
protease calpain-2 [15, 38, 39, 43, 44]. In our system,
however, the simultaneous increase of the regulatory cal-
pain 2 subunit CAPNS1, argues for overall little change
in FA turnover, at least in absence of TGF-β1 (Fig. 2c,
d). This is consistent with our observation that phos-
phorylation levels of FAK, Src, and ERK (Fig. 3), central
signaling events in the process of FA turnover [39, 56–58]
remained unchanged.
At first, observing inhibition of adhesion and migra-
tion in the absence of changes in activation of FAK and
related signaling pathways seemed contradictory to us.
However, similarly, Asano and colleagues have reported
that siRNA-mediated knockdown of α-smooth muscle
actin (α-SMA) in phLF led to inhibition of migration
without affecting the FAK signaling pathway [59]. This
observation suggested that changes in actin dynamics
may underlie the observed inhibition of migration and,
indeed, from our previous studies, we know that FKBP10
deficiency reduces α-SMA expression in phLF [22]. Also,
deficiency of the actin binding protein CORO1C typic-
ally results in inhibition of migration; however, here, we
observed a moderate increase of CORO1C protein ra-
ther than downregulation (Fig. 2i) [60, 61]. Expression of
CAV1, deficiency of which typically results in decreased
migratory speed in variable cell types [62–64], was only
moderately downregulated in presence of TGF-β1
(Fig. 2g, h). Collectively, these observations do not
argue for altered actin dynamics as a major mechan-
ism underlying inhibition of migration in response to
FKBP10 deficiency.
Importantly, cell migration is influenced by properties
of the ECM, like density of adhesion ligands (collagen,
FN), ECM composition, and stiffness [7, 65]. Previously,
we have observed downregulation of expression and se-
cretion of type I collagen and FN, both major compo-
nents of the fibroblast ECM, in response to FKBP10
knockdown [22]. Here we extended this analysis and
assessed additional ECM components with important
roles in cell migration, namely type VI collagen and
FBLN1. Both proteins colocalized with FKBP10 in phLF,
as assessed by both immunofluorescence colocalization
analysis and proximity ligation assay (Fig. 4g-j), indicat-
ing direct interaction with FKBP10 in the ER. Interest-
ingly, we found that loss of FKBP10 significantly
increased FBLN1 expression (Fig. 4e, f ), but decreased
protein levels of COL6A1 (Fig. 4a, b). Notably, COL6A1
deficiency is sufficient to inhibit collagen VI deposition
in the ECM, as no triple helical molecules can be formed
without the α1(VI)-chain [66]. These results suggest op-
posing functions of FKBP10 in FBLN1 and collagen VI
biosynthesis in phLF. It is tempting to speculate, for in-
stance, that FKBP10 acts as a FBLN1 chaperone, seques-
tering FBLN1 in the ER, prohibiting packing in vesicles
for secretion or targeting FBLN1 for ER-associated pro-
tein degradation, while at the same time FKBP10 is likely
required for efficient collagen VI triple helix formation,
similar to collagen I and III [21, 67, 68]. These aspects
will be interesting to explore in future studies.
As to function of these proteins in migration, reduced
attachment and decreased migratory speed has been re-
ported for a human breast cancer cell line (MDA
MB231) in response to FBLN1 overexpression [27] and
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siRNA mediated knockdown of FBLN1 in corneal fibro-
blasts upregulated cell migration [69]. Therefore, taken
together, it was plausible that increased FBLN1 levels
may underlie the observed inhibition of migration under
conditions of FKBP10 deficiency.
While collagen VI begins to emerge as an important
regulator of cell migration, reports on its direction of ef-
fect, inhibiting or promoting migration, are controversial
[18–20]. For instance, collagen VI-deficient tendon fi-
broblasts show delayed wound closure, i.e. lower migra-
tion speed, in a scratch assay [18], while human dermal
fibroblasts displayed higher migration speed on matrices
derived from collagen VI-deficient cells [20]. These dis-
crepancies may be a result of the divergent approaches
in the mentioned studies (assessment of newly formed
ECM versus assessment of ECM deposited within 10
days, respectively), different collagen VI chains assessed
(COL6A1 versus COL6A2), but also of the different cell
origins, thus possibly reflecting time-, chain-, and cell-
specific effects of collagen VI.
Ascorbic acid is a cofactor necessary for proline and
lysine hydroxylation during collagen synthesis [68] in-
cluding collagen VI [30, 70], but not required for FBLN1
synthesis. Therefore, to differentiate between increased
FBLN1 or decreased type VI collagen as the underlying
mechanism of decreased adhesion and migration, we
compared effects of FKBP10 knockdown on adhesion
and migration in absence and presence of 2-
phosphoascorbate, a stable analogue of ascorbic acid.
Notably, neither migration nor adhesion were changed
upon loss of FKBP10 when the cell culture medium was
ascorbate-deficient (Fig. 5a, b). These results strongly in-
dicated that the effect of FKBP10 deficiency on adhesion
and migration was collagen-dependent. While coating
with collagen VI abolished the effect of FKBP10 knock-
down on migration completely, coating with collagen I
only did so marginally (Fig. 6). Overall, this indicated
that FKBP10 knockdown inhibits lung fibroblast migra-
tion by reduced collagen VI biosynthesis rather than
reduced collagen I biosynthesis, an effect of FKBP10
deficiency which we have reported previously [22].
Conclusion
Collagen VI is an important regulator of the ECM or-
ganizing the three-dimensional meshwork of collagen
and FN fibers [71, 72] and the topography of the fibrillar
ECM network guides directional cell migration [73].
Therefore, our observations suggest that loss of FKBP10
results in reduced biosynthesis of collagen VI and, pos-
sibly in combination with decreased extracellular colla-
gen I levels, leads to a disorganized ECM with changed
adhesion ligand density, stiffness and composition,
which may not provide sites for integrin clustering and
does not favor directional cell migration. Upregulation
of ITGB1, TLN1, CAPNS1, total FAK, and CORO1C
may ultimately reflect an attempt of the cells to over-
come decreased migration by overcompensation, in-
creasing expression of ECM receptors or components of
the FA turnover machinery.
Interestingly, FKBP10 mediates dimerization with col-
lagen lysyl hydroxylase 2 and thus contributes to the
generation of collagen hydroxylysines, which act as sub-
strates for extracellular lysyl-oxidase-mediated collagen
crosslinking [74–76]. Extracellular collagen lacking
proper crosslinks is prone to proteolytic degradation and
may not be able to contribute to the higher ordered
organization of the ECM anymore [77–80]. Therefore,
downregulation of FKBP10 may also contribute to
disorganization of the ECM by providing less crosslink-
ing sites in type I and type VI collagen.
In summary, we found that loss of FKBP10 in phLF re-
sults in decreased adhesion and migration. We found
that the main underlying mechanism was reduced colla-
gen VI biosynthesis, as both ascorbate deficiency and
coating of cell culture dishes with collagen VI abolished
the effect of FKBP10 knockdown on migration. As in-
creased fibroblast migration is a characteristic of IPF, the
results are in support of our concept of FKBP10 as a po-
tential drug target for IPF.
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Abstract
Idiopathic pulmonary fibrosis (IPF) is characterized by excessive
deposition of extracellular matrix, in particular, collagens. Two
IPF therapeutics, nintedanib and pirfenidone, decelerate lung
function decline, but their underlying mechanisms of action are
poorly understood. In this study, we sought to analyze their effects
on collagen synthesis and maturation at important regulatory levels.
Primary human fibroblasts from patients with IPF and healthy
donors were treated with nintedanib (0.01–1.0 mM) or pirfenidone
(100-1,000 mM) in the absence or presence of transforming growth
factor-b1. Effects on collagen, fibronectin, FKBP10, and HSP47
expression, and collagen I and III secretion, were analyzed by
quantitative polymerase chain reaction and Western blot. The
appearance of collagen fibrils was monitored by scanning electron
microscopy, and the kinetics of collagen fibril assembly was assessed
using a light-scattering approach. In IPF fibroblasts, nintedanib
reduced the expression of collagen I and V, fibronectin, and FKBP10
and attenuated the secretion of collagen I and III. Pirfenidone also
down-regulated collagen V but otherwise showed fewer and less
pronounced effects. By and large, the effects were similar in donor
fibroblasts. For both drugs, electron microscopy of IPF fibroblast
cultures revealed fewer and thinner collagen fibrils compared
with untreated controls. Finally, both drugs dose-dependently
delayed fibril formation of purified collagen I. In summary, both
drugs act on important regulatory levels in collagen synthesis and
processing. Nintedanib was more effective in down-regulating
profibrotic gene expression and collagen secretion. Importantly,
both drugs inhibited collagen I fibril formation and caused a
reduction in and an altered appearance of collagen fibril
bundles, representing a completely novel mechanism of action
for both drugs.
Keywords: idiopathic pulmonary fibrosis; extracellular matrix;
nintedanib; pirfenidone
Clinical Relevance
Accumulation of extracellular matrix, mainly collagen, is
a main feature of idiopathic pulmonary fibrosis (IPF).
Nintedanib and pirfenidone, two recently approved
therapeutics for IPF, decelerate disease progression, but
their antifibrotic mechanisms of action are incompletely
understood. To the best of our knowledge, this study provides
the first evidence for the inhibition of collagen fibril formation
as a major mechanism of action for nintedanib and pirfenidone
and puts forward extracellular collagen self-assembly as a
druggable target in IPF.
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Idiopathic pulmonary fibrosis (IPF) is a
progressive and fatal interstitial lung disease
with a median survival of 3–5 years after
diagnosis (1). The underlying pathogenic
processes are poorly understood, but the
aberrant fibrotic response is likely initiated
by repeated microinjuries to the airway and
the alveolar epithelium (2). This leads to
the secretion of fibrotic mediators,
including transforming growth factor b
(TGF-b), which results in the accumulation
of myofibroblasts in alveolar regions.
Multiple progenitor cells may contribute to
the myofibroblast population, but the most
well-established source is the interstitial
fibroblast (3). Myofibroblasts synthesize
and deposit excessive amounts of
extracellular matrix (ECM) proteins, such
as collagen type I, III, and V, and
fibronectin (4). The resulting accumulation
of ECM in the alveolar region is the
ultimate pathological feature of lung
fibrosis, leading to progressive lung
function decline (5).
A recent study highlights that collagens
are the main components of newly
synthesized ECM in lung fibrosis (6), but
large-scale quantitative proteome
approaches have also demonstrated that the
ECM composition (the matrisome) is far
more complex than previously assumed (7).
In addition, the complexity of collagen
biosynthesis and maturation is rarely
taken into account in mechanistic
studies of the evaluation of antifibrotic
strategies. Collagen modification and
folding in the rough endoplasmic
reticulum (rER) requires several enzymes
and molecular chaperones essential for
post-translational modifications (PTMs)
and the processing of procollagen into
triple helices, where one of the rate-limiting
steps is the cis-trans isomerization of
proline residues catalyzed by rER resident
peptidyl prolyl isomerases (8). Collagen
triple helix formation is followed by its
secretion, extracellular fibril formation,
and fiber assembly (9). Two endoplasmic
reticulum proteins participating in this
multistep process are the collagen
chaperones FK506-binding protein 10
(FKBP10, also called FKBP65) and heat-
shock protein 47 (HSP47, also called
SerpinH1) (9). Notably, both FKBP10 and
HSP47 are up-regulated in bleomycin-
induced lung fibrosis and in IPF (10, 11).
Secretion of procollagen from HSP47-
deficient fibroblasts is reduced compared
with control cells (12) and similarly,
knockdown of FKBP10 in IPF fibroblasts
decreases collagen type I synthesis and
secretion (10). In addition, PTMs such as
hydroxylation of lysyl or prolyl residues, or
glycosylation of hydroxylysines, are
essential for proper stability, assembly, and
secretion of procollagen, as well as for the
final supramolecular structure of these
molecules (13). For example,
hydroxylation of proline residues on
position three (3-Hyp) might play a role
in inter-triple-helical interactions and
probably assists in the assembly of
supramolecular collagen and lateral fibril
growth (14, 15).
Nintedanib and pirfenidone were
approved recently for IPF therapy, because
both drugs have been shown to slow down
disease progression as measured by
reduced lung function decline. Despite their
widespread application in IPF in recent
times, their mechanisms of action are
poorly understood and remain to be fully
elucidated (16, 17). Nintedanib, originally
developed as an anticancer drug, is a
receptor tyrosine kinase inhibitor of
platelet-derived growth factor receptor,
fibroblasts growth factor receptor, and
vascular endothelial growth factor receptor,
all of which play important roles in the
pathogenesis of IPF (5). Pirfenidone is an
antifibrotic, antiinflammatory, and
antioxidant compound with beneficial effects
in lung, hepatic, kidney, and cardiac
fibrosis, but its direct targets are unknown
(18, 19, 20). Several studies have investigated
the effects of either nintedanib or
pirfenidone on collagen type I expression or
secretion in several cell types (10, 21–26). No
study to date, however, has directly
compared both drugs on the multiple stages
of intracellular collagen synthesis and
extracellular maturation in the relevant cell
type (i.e., the primary human lung
fibroblast).
Therefore, the aim of our study was
to comprehensively assess and directly
compare the effects of nintedanib and
pirfenidone on the different steps of collagen
synthesis and maturation in primary human
lung fibroblasts (phLF) from patients with
IPF and healthy donors. We analyzed the
expression of various collagens and the
collagen chaperones FKBP10 and HSP47, as
well as collagen secretion in IPF and
healthy phLF. In addition, we examined the
effects of both drugs on the levels of
selected PTMs of collagen in IPF fibroblasts
and on collagen fibril formation.
Materials and Methods
For more details on materials and methods,
see the online supplement. Statistical
analysis was performed in GraphPadPrism
7.02 (GraphPad Software, San Diego, CA).
MTT Cytotoxicity Assay
See the online supplement.
Human Lung Material and Culture
of phLF
Primary human lung fibroblasts, isolated
from human lung explant material of
patients with IPF or healthy donors, were
obtained from the BioArchive CPC-M
for lung diseases at the Comprehensive
Pneumology Center (CPC, Munich,
Germany). All participants gave written
informed consent, and the study was
approved by the local ethics committee
of the Ludwig-Maximilians University
of Munich, Germany. Isolation of
phLF was performed as described previously
(10). For more details, see the online
supplement.
Cotreatment of IPF and Donor phLF
with TGF-b1 and Nintedanib or
Pirfenidone
Cells were seeded at a density of
20,000–25,000 cells/cm2, followed by
starvation for 24 hours in starvation
medium (Dulbecco’s modified Eagle
medium/F12, 0.5% fetal bovine serum,
penicillin/streptomycin, 0.1 mM 2-
phospho-L-ascorbic acid). Subsequently,
cells were treated with or without TGF-b1
(2 ng/ml) (R&D Systems, Minneapolis,
MN) and with nintedanib (0.01 mM,
0.1 mM, 1.0 mM) or pirfenidone (100 mM,
500 mM, 1,000 mM) (both Selleck, Houston,
TX) for 48 hours in starvation medium.
Nintedanib and pirfenidone were dissolved
in dimethyl sulfoxide. The final dimethyl
sulfoxide concentration in the medium was
always 1%.
RNA Isolation and Real-Time
Quantitative Reverse-Transcriptase
Polymerase Chain Reaction Analysis
See the online supplement.
Protein Isolation and Western Blot
Analysis
See the online supplement.
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Quantification of Secreted Collagen
Collagen I and III were precipitated from
cell culture supernatant of cultured IPF and
donor phLF as described previously (10).
For more details, see the online supplement.
Collagen Precipitation and Analysis
of PTM
See the online supplement.
Scanning Electron Microscopy for
Assessment of Fibrils in the ECM
of phLF
IPF phLF were grown on glass slides, treated
with nintedanib (1 mM) or pirfenidone
(1,000 mM) in combination with TGF-b1
(2 ng/ml) for 48 hours and fixed with
paraformaldehyde and glutaraldehyde, 3%
each, in 0.1% sodium cacodylate buffer pH
7.4 (Electron Microscopy Sciences, Munich,
Germany). The specimens were dehydrated
in gradual ethanol and dried by the critical-
point method, using CO2 as the transitional
fluid (Polaron Critical Point Dryer CPC
E3000; Quorum Technologies, Ringmer,
UK). Specimens were sputter coated with a
thin layer of platinum by a sputtering
device (Emitech K575; Quorum
Technologies) and observed by scanning
electron microscopy (JSM 6300F; JEOL,
Eching, Germany). Fibril thickness was
assessed by measuring the diameter of the
smallest unit of fiber forming fibrils, using
the length measurement tool of the open
source software ImageJ 1.50i (W.S.
Rasband, National Institutes of Health,
Bethesda, MD).
Collagen I Fibril Formation Assay
This assay was performed essentially as
described previously (27). For more details,
see the online supplement.
Results
Applied Concentrations of Nintedanib
and Pirfenidone Were Well Tolerated
by IPF phLF
For in vitro experiments, we selected a
range of nintedanib and pirfenidone
concentrations similar to those used in
published studies (22, 23, 25). Notably, for
pirfenidone, in an effort to adhere to
physiologically relevant concentrations, we
used 1,000 mM as the highest
concentration, although others have used
pirfenidone in concentrations of up to
10 mM in similar experiments (21, 26, 28).
Initially, we analyzed the effect of
increasing doses of nintedanib (0.01–1 mM)
and pirfenidone (100-1,000 mM) on the
viability of IPF fibroblasts in an MTT assay.
The used concentrations of nintedanib and
pirfenidone were well tolerated for the
treatment period of 48 hours (see Figure E1
in the online supplement).
Nintedanib Reduced the Expression
and Secretion of ECM Components
More Effectively Than Did Pirfenidone
in phLF
Next, we assessed the effect of different
concentrations of both drugs on the
expression and secretion of collagen I
(COL1A1), III (COL3A1), V (COL5A1),
fibronectin 1 (FN1), and plasminogen
activator inhibitor 1 (PAI-1) in lysates and
cell culture supernatants from primary
human IPF and donor fibroblasts.
Nintedanib consistently down-regulated
transcript and protein levels of basal and
TGF-b1–induced collagen I in IPF phLF
(Figures 1A, 1C, 1E, and 1G). Pirfenidone
reduced TGF-b1–induced COL1A1
transcripts only marginally (Figures 1A and
1C), and collagen I protein remained largely
unchanged (Figures 1E and 1G). Similar
tendencies were observed in phLF isolated
from healthy donor lungs (Figures 1B, 1D,
and 1F), with the exception of COL1A1
transcript (Figure 1B) and levels of basal
secreted collagen I (Figure 1H), which both,
in contrast to IPF, appeared unaffected by
nintedanib in donor fibroblasts.
Similarly, the expression of collagen III
was consistently down-regulated by
nintedanib in IPF fibroblasts on transcript
and protein levels, whereas pirfenidone
merely regulated COL3A1 transcripts, an
effect which again did not translate to
protein level (Figures 2A, 2C, and 2E).
Interestingly, in donor fibroblasts,
nintedanib increased and pirfenidone
decreased COL3A1 transcription (Figures
2B and 2D), whereas the amount of
secreted collagen III remained largely
unchanged or even tended to anticorrelate
with transcript levels (Figure 2F).
As for collagen V, TGF-b1–induced
collagen V was significantly reduced in IPF
fibroblasts by both drugs, an effect that was
captured only partly at the transcript level
(Figures 3A, 3C, and 3E); similar trends
were observed in donor phLF (Figures 3B,
3D, and 3F).
Expression of FN1 was consistently
decreased by nintedanib on transcript and
protein levels, in both IPF and donor
fibroblasts (Figure E2). In contrast,
pirfenidone reduced FN1 mRNA, but not
protein levels, in IPF fibroblasts (Figures
E2A, E2C, and E2E) and had no significant
effect in donor phLF (Figures E2B, E2D,
and E2F). Interestingly, pirfenidone
actually showed a trend to increase FN1
protein levels in both IPF and donor phLF
(Figures E2E and E2F). Expression of
PAI-1, a classic TGF-b–induced gene, was
reduced significantly by nintedanib in
IPF and donor fibroblasts, with a more
pronounced effect in the absence of
TGF-b1 (Figure E3). Pirfenidone did not
affect PAI-1 expression.
In summary, in comparison with
nintedanib, pirfenidone showed fewer
effects on collagen expression and secretion
and FN1 and PAI-1 expression. Notably,
exceeding the effective concentration of
nintedanib at by least 500 times, a
concentration of 500 to 1,000 mM
pirfenidone was necessary to achieve
significant effects (e.g., on collagen I,
III, and V and FN1 expression) in
TGF-b1–treated IPF fibroblasts (Figures
1A, 2A, 3E, and E2A).
Nintedanib, but Not Pirfenidone,
Reduces the Expression of the
Collagen Chaperone FKBP10 in
IPF Fibroblasts
Next, we investigated the effects of
nintedanib and pirfenidone on the
expression of FKBP10 and HSP47, two
collagen I chaperones. Nintedanib
moderately, but significantly, down-
regulated protein levels of FKBP10 in
mock- as well as in TGF-b1–treated IPF
fibroblasts (Figure 4E). This effect was
already visible on the transcript level for
TGF-b–treated samples (Figures 4A and
4C). In contrast, pirfenidone did not
influence FKBP10 expression in IPF
fibroblasts (Figures 4A, 4C, and 4E).
Interestingly, clearly different results
were obtained with donor fibroblasts
here, where nintedanib failed to
regulate FKBP10 expression, and
pirfenidone down-regulated FKBP10
transcript but up-regulated FKBP10
protein levels (Figures 4B, 4D, and 4F).
Regarding the expression of the major
collagen I chaperone HSP47, neither drug
reduced HSP47 protein levels in phLF
(Figures 5E and 5F), even if both
therapeutics decreased basal HSP47 mRNA
(Figures 5A–5D).
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Figure 1. Nintedanib decreases collagen I expression and secretion more potently than does pirfenidone in idiopathic pulmonary fibrosis (IPF) fibroblasts.
(A–D) Quantitative RT-PCR analysis of primary human lung fibroblasts (phLF) isolated from (A and C) patients with IPF or (B and D) healthy donors treated for
48 hours with increasing concentrations of nintedanib (0.01, 0.1, and 1 mM) or pirfenidone (100, 500, and 1,000 mM) in the absence or presence of
transforming growth factor b (TGF-b) 1 (2 ng/ml). Transcript levels of COL1A1 are shown as2DCt values (A and B) as well as transcript fold changes (C and D)
to show the effect normalized to control (ctrl). DEAH (Asp-Glu-Ala-His) box polypeptide 8 (DHX8) was used as endogenous control. Data are based on
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Selected Post-Translational
Modifications of Collagen I Are Not
Affected by Nintedanib or Pirfenidone
PTMs have a major impact on essential
collagen properties such as the three-
dimensional structure, thermodynamic
stability, and biological functions (13, 14,
15), but, to date, whether antifibrotic drugs
affect the PTMs of collagen secreted by IPF
fibroblasts has not been assessed. Here, we
tested whether nintedanib and pirfenidone
affected the levels of selected PTMs of
collagen I. More specifically, we compared
the levels of prolyl-3-hydroxylation of the
A1 site (Pro-986) and the A3 site (Pro-707)
of the collagen a1 chain (15), prolyl-3-
hydroxylation of the A3 site (Pro-707) of
the collagen a2 chain and, finally, the
glycosylation site of hydroxylysine (Lys-
174) of collagen type I. Neither drug
appeared to affect the levels of the assessed
PTMs (Figure E4).
Nintedanib and Pirfenidone Affect
Collagen Fibril Formation in IPF
Fibroblasts
Scanning electron microscopy was used to
assess the number, morphology, and
thickness of extracellular fibrils formed in
cultures of TGF-b1–treated IPF fibroblasts
in the absence and presence of nintedanib
or pirfenidone. Extracellular collagen fibers
were identified as unbranched and dense
bundles of thread-like–looking twisted
fibrils of variable length, which were
oriented randomly, and with a maximal
diameter of 1 mm (Figure 6A) (29, 31). Cell
cultures that had been treated with 1.0 mM
nintedanib or 1.0 mM pirfenidone
displayed a markedly reduced number of
fibers and changes in overall fiber structure.
In the presence of both drugs, fibers were
shorter overall and showed a more frayed
appearance than in control samples, and
the fibril thickness was significantly
reduced in nintedanib- and pirfenidone-
treated samples compared with control
fibrils (Figure 6B).
Nintedanib and Pirfenidone Inhibit
Spontaneous Collagen I Fibril
Formation
It seemed unlikely that the effects on
collagen fibril formation observed by
scanning electron microscopy could be
accounted for by the effects of both drugs on
collagen synthesis and secretion only, in
particular in the case of pirfenidone.
Therefore, we investigated the direct effect
of both drugs on spontaneous collagen I
fibril formation in a light-scattering
approach. This assay is a well- established
method of studying the formation of
collagen fibrils in a solution of purified
soluble collagen I. It relies on the principle
that collagen I, dissolved initially in dilute
acid, spontaneously forms fibrils on
neutralization in a self-driven process. The
resulting fibrils are similar to those formed
in vivo, and the process can be visualized by
dynamic light scattering at 313 nm (30, 31).
We found that both therapeutics were able
to considerably delay fibril formation of
purified collagen I already at micromolar
concentrations in a dose-dependent
manner (Figure 7 and Table 1).
Discussion
In this study, we demonstrated that
nintedanib and pirfenidone affect collagen
synthesis and maturation on several
regulatory levels, including the inhibition of
collagen gene expression, collagen secretion,
and, most importantly, fibril formation.
In terms of intracellular regulation of the
synthesis of ECM components and collagen
secretion, nintedanib was clearly more
effective, because it (1) exerted its effects at
substantially lower concentrations (up to
1,000-fold) than did pirfenidone, (2)
affected the expression and secretion of
more ECM and ECM-related genes
(i.e., fibronectin, FKBP10, and collagen I),
and (3) showed more consistent effects on
transcript and protein levels. With few
exceptions, these effects were mostly similar
in IPF and donor fibroblasts. Importantly,
both drugs strongly inhibited extracellular
fibril formation, and assessment of
spontaneous fibril assembly using purified
collagen I indicated that both drugs directly
inhibited this process with comparable
efficiency.
Both nintedanib and pirfenidone
inhibited TGF-b–induced transcription of
COL1A1, COL3A1, and FN1. In agreement,
previous reports by others have shown
that nintedanib and pirfenidone counteract
TGF-b signaling and down-regulate these
TGF-b target genes (23, 24, 32). Although
pirfenidone showed these effects only in the
presence of exogenously added TGF-b1,
nintedanib also affected basal levels of
COL1A1 in IPF fibroblasts and basal levels
of another TGF-b target gene, PAI-1, in
both IPF and donor fibroblasts (Figures 1A
and E3). The platelet-derived growth factor
receptor (PDGFR) and the fibroblast
growth factor receptor are known targets of
the receptor tyrosine kinase inhibitor
nintedanib, and this might reflect the
inhibition of autocrine platelet-derived
growth factor or fibroblast growth factor
signaling, which has been shown to regulate
collagen gene expression (5, 33, 34) via both
the ERK and the PI3K/Akt signaling
pathways (35). In agreement,
phosphorylation of Akt was decreased in
Figure 1. (Continued). seven (IPF) or three (donor) completely independent experiments and are presented as mean6 SEM. Statistical significance
between control and different concentrations of nintedanib or pirfenidone is indicated by horizontal brackets and asterisks for 2DCt values and by
asterisks only for fold changes relative to 1. (E and F ) Western blot analysis of phLF isolated from (E ) patients with IPF or (F ) donors treated for 48 hours with
increasing concentrations of nintedanib (0.01, 0.1, and 1 mM) or pirfenidone (100, 500, and 1,000 mM) in the absence or presence of TGF-b1 (2 ng/ml).
Densitometric analysis and representative blots show the effect of nintedanib and pirfenidone on collagen I (Col I) protein expression relative to b-actin as
loading control. Data are based on eight (IPF) or three (donor) completely independent experiments and are presented as mean6 SEM. Statistical significance
between control and different concentrations of nintedanib or pirfenidone is indicated by horizontal brackets and asterisks. (G and H) Western blot
analysis of secreted Col I precipitated from cell culture supernatant of (G) IPF or (H) donor fibroblasts treated for 48 hours with increasing concentrations of
nintedanib (0.01, 0.1, and 1 mM) or pirfenidone (100, 500, and 1,000 mM) in the absence or presence of TGF-b1 (2 ng/ml). Densitometric analysis and
representative blots show the effects of nintedanib and pirfenidone on secreted Col I after 48 hours. Data are based on seven (IPF) or three (donor) completely
independent experiments and are given as mean6 SEM. Statistical significance between control and different concentrations of nintedanib or pirfenidone
is indicated by horizontal brackets and asterisks. Statistical analysis was performed by one-way analysis of variance (post-test, Bonferroni‘s multiple
comparison test: comparison against control). *P, 0.1, **P, 0.01, ***P, 0.001, ****P, 0.0001. The well-known effect of TGF-b1 on these transcripts
and proteins was significant, but it is not specified in the interest of clarity.
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Figure 2. COL3A1 transcription is decreased by nintedanib in IPF fibroblasts and increased in donor fibroblasts, whereas collagen III (Col III)
secretion is decreased in both. (A–D) Quantitative RT-PCR analysis of phLF isolated from (A and C) patients with IPF or (B and D) healthy donors treated
for 48 hours with increasing concentrations of nintedanib (0.01, 0.1, and 1 mM) or pirfenidone (100, 500, and 1,000 mM) in the absence or presence of
TGF-b1 (2 ng/ml). Transcript levels of COL3A1 are shown as 2DCt values (A and B) as well as transcript fold changes (C and D) to show the effect
normalized to control. DHX8 was used as endogenous control. Data are based on seven (IPF) or three (donor) completely independent experiments and
are given as mean6 SEM. Statistical significance between control and different concentrations of nintedanib or pirfenidone is indicated by horizontal
brackets and asterisks for 2DCt values and by asterisks only for fold changes relative to 1. The well-known effect of TGF-b1 on these transcripts
was significant, but it is not specified in the interest of clarity. (E and F ) Western blot analysis of secreted Col III precipitated from cell culture supernatant of
(E ) IPF or (F ) donor fibroblasts after treatment of phLF isolated from patients with IPF treated for 48 hours with increasing concentrations of nintedanib
(0.01, 0.1, and 1 mM) or pirfenidone (100, 500, and 1,000 mM) in the absence or presence of TGF-b1 (2 ng/ml). Densitometric analysis and representative
blots show the effects of nintedanib and pirfenidone on secreted Col III after 48 hours. Data are based on seven (IPF) or three (donor) completely
independent experiments and are given as mean6 SEM. Statistical significance between control and different concentrations of nintedanib or pirfenidone
is indicated by horizontal brackets and asterisks. Statistical analysis was performed by one-way analysis of variance (posttest, Bonferroni‘s multiple
comparison test: comparison against control). *P, 0.1.
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Figure 3. Nintedanib and pirfenidone down-regulate collagen V (Col V ). (A–D) Quantitative RT-PCR analysis of phLF isolated from (A and C) patients with
IPF or (B and D) healthy donors treated for 48 hours with increasing concentrations of nintedanib (0.01, 0.1, and 1 mM) or pirfenidone (100, 500, and
1,000 mM) in the absence or presence of TGF-b1 (2 ng/ml). Transcript levels of (A and C) IPF and (B and D) donor phLF of COL5A1 are shown as 2DCt
values (A and B) as well as transcript fold changes (C and D) to show the effect normalized to control (ctrl). DHX8 was used as endogenous control.
Data are based on seven (IPF) or three (donor) completely independent experiments and are given as mean6 SEM. Statistical significance between
control and different concentrations of nintedanib or pirfenidone is indicated by horizontal brackets and asterisks for 2DCt values and by asterisks only for
fold changes relative to 1. (E and F ) Western blot analysis of phLF isolated from (E ) patients with IPF or (F) healthy donors treated for 48 hours with
increasing concentrations of nintedanib (0.01, 0.1, and 1 mM) or pirfenidone (100, 500, and 1,000 mM) in the absence or presence of TGF-b1 (2 ng/ml).
Densitometric analysis and representative blots show the effect of nintedanib and pirfenidone on Col V protein expression relative to b-actin. Data are
based on eight (IPF) or three (donor) completely independent experiments and are given as mean6 SEM. Statistical significance between control and
different concentrations of nintedanib or pirfenidone is indicated by horizontal brackets and asterisks. Statistical analysis was performed by one-way
analysis of variance (posttest, Bonferroni‘s multiple comparison test: comparison against control). *P, 0.1. The well-known effect of TGF-b1 on these
transcripts and proteins was significant, but it is not specified in the interest of clarity.
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Figure 4. Expression of the collagen chaperone FKBP10 is consistently down-regulated by nintedanib in IPF but regulated more dynamically by
pirfenidone in donor fibroblasts. (A–D) Quantitative RT-PCR analysis of phLF isolated from (A and C) patients with IPF or (B and D) healthy
donors treated for 48 hours with increasing concentrations of nintedanib (0.01, 0.1, and 1 mM) or pirfenidone (100, 500, and 1,000 mM) in the absence
or presence of TGF-b1 (2 ng/ml). Transcript levels of (A and C) IPF and (B and D) donor phLF of FKBP10 are shown as 2DCt values (A and B) as
well as transcript fold changes (C and D) to show the effect normalized to control. DHX8 was used as endogenous control. Data are based on seven
(IPF) or three (donor) completely independent experiments and are given as mean6 SEM. Statistical significance between control and different
concentrations of nintedanib or pirfenidone is indicated by horizontal brackets and asterisks for 2DCt values and by asterisks only for fold
changes relative to 1. (E and F) Western blot analysis of phLF isolated from (E ) patients with IPF or (F ) healthy donors treated for 48 hours
with increasing concentrations of nintedanib (0.01, 0.1, and 1 mM) or pirfenidone (100, 500, and 1,000 mM) in the absence or presence of TGF-b1
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response to nintedanib in all our
experiments (Figures E5A and E5B). In
contrast, phosphorylation of ERK was not
consistently changed, either in IPF or in
donor fibroblasts (Figures E5C and E5D).
In light of the time point studied (48 h after
treatment start), this argues for a stronger
and more sustained inhibition of the
PI3K/Akt signaling pathway by nintedanib
in our studies. Inhibition of PDGFR
signaling, however, cannot explain all our
in vitro results, because a previous study
from our laboratory (34) found that small
interfering RNA–mediated down-
regulation of PDGFR-a actually increased
levels of collagen V drastically in primary
human lung fibroblasts, which is in contrast
to what we observed in the presence of
nintedanib.
It is striking that many of the observed
effects translated to the protein level only
in the presence of nintedanib, but not
pirfenidone. For instance, both drugs inhibit
TGF-b–induced COL1A1, COL3A1, and
FN1 transcription, whereas the levels of
collagen I protein, secreted collagen III, and
fibronectin protein were reduced only by
nintedanib in IPF fibroblasts (Figures 1, 2,
and E2). These results suggest that post-
transcriptional regulation mechanisms are
affected differently by the drugs and
highlight the importance of analysis at the
protein level in this context. Nevertheless,
other studies have reported effects of
pirfenidone on collagen I and/or
fibronectin protein levels in normal phLF
(26), alveolar epithelial cells (21), and nasal
polyp fibroblasts (28). These discrepancies,
however, may be the result of the use of
substantially higher concentrations of
pirfenidone in those studies (1.6–10 mM).
Notably, during standard treatment with
pirfenidone of patients with IPF (three daily
doses of 801 mg pirfenidone), serum levels
of pirfenidone do not exceed 100 mM (36),
a concentration at which we did not
observe any effect on phLF gene expression.
Both nintedanib and pirfenidone
significantly down-regulated collagen V in
IPF fibroblasts, and a similar trend was
observed in donor fibroblasts (Figures 3E
and 3F). To our knowledge, down-
regulation of collagen V levels in response
to nintedanib or pirfenidone has not
been reported before. Type V collagen is
a minor component of collagen type I
fibrils that plays an important role in
fibrogenesis and regulation of fiber size
(37–39). In IPF lungs, collagen V is heavily
overexpressed compared with that in
normal lungs (38). Importantly, in the
context of the observed effects on fibril
thickness (Figure 6B), collagen V has been
shown to be crucial for the initiation of
collagen fibril assembly (39). Therefore,
down-regulation of collagen V by both
drugs likely contributes to the phenomenon
of fewer and thinner fibrils in the
extracellular space of primary human IPF
fibroblasts described here (Figure 6).
Interestingly, Hostettler and colleagues (25)
found that matrix metalloprotease 2, an
ECM metalloprotease that cleaves collagen
V, is up-regulated, and its inhibitor,
metalloproteinase inhibitor 2 (TIMP2), is
down-regulated in response to nintedanib.
This provides indirect evidence for
increased extracellular degradation of
collagen V, and, collectively, this suggests
that nintedanib may decrease collagen V
via both an intracellular and an
extracellular mechanism.
To date, few studies have assessed the
effects of nintedanib and pirfenidone on
collagen secretion. Previously, using Sirius
Red–based quantification of total collagen
in cell culture supernatant, we showed
that nintedanib, but not pirfenidone, dose
dependently inhibited collagen secretion in
IPF fibroblasts (10). Similarly, Hostettler
and colleagues reported a reduction of total
secreted collagens in IPF and control
fibroblasts on nintedanib treatment (25).
Because collagen I and III are the most
abundant fibrillar collagens in the lung
interstitium and both are known to
be increased in IPF (40), we further
characterized the inhibition of collagen
secretion by both drugs, looking at these
two specific collagen subtypes in this study.
Clearly, nintedanib was more effective
in inhibiting basal collagen I and
TGF-b–induced collagen III secretion.
Pirfenidone showed only weak inhibitory
effects on basal collagen I secretion
(Figure 1G), and, notably, no significant
effects on collagen III secretion (Figure 2E).
Given the observed inhibitory effect of
nintedanib on total collagen secretion in
our previous study (10), this suggests that
nintedanib-induced down-regulation of
collagen III secretion contributes more
strongly to the decrease of total secreted
collagen than does collagen I in IPF
fibroblasts.
FKBP10 and HSP47 are rER-resident
chaperones, critical for the proper folding of
triple-helical procollagen (9, 12). Deficiency
of both proteins leads to changes in the
extracellular appearance of collagen fibrils
as, for example, reduced collagen
crosslinking (41, 42) or aberrant fibril
formation (12). Both collagen chaperones
are increased in animal models of
bleomycin-induced lung fibrosis and in
patients with IPF (7, 10, 11), and we
showed recently that small interfering
RNA–mediated down-regulation of
FKBP10 attenuates the expression and
secretion of collagen in pHLF (10).
Interestingly, it had been reported in two
independent studies that pirfenidone
down-regulated the expression of HSP47 in
A549 cells and human lung fibroblasts,
which suggested that pirfenidone exerted its
antifibrotic effects in part via the inhibition
of intracellular collagen folding (21, 26).
Therefore, we also assessed the regulation
of HSP47 and FKBP10 by nintedanib and
pirfenidone in IPF and donor fibroblasts.
Notably, nintedanib marginally, but
significantly, down-regulated TGF-
b–induced FKBP10 expression on
transcript and protein levels in IPF
fibroblasts, whereas pirfenidone had no
effect (Figures 4A, 4C, and 4E). Strikingly, a
different pattern was observed here for
donor fibroblasts: FKBP10 expression
remained unaffected by nintedanib, but
decreased at the transcript and increased
at the protein level by pirfenidone
(Figures 4B, 4D, and 4F). Regarding HSP47
expression, neither drug had an effect on
Figure 4. (Continued). (2 ng/ml). Densitometric analysis and representative blots show the effect of nintedanib and pirfenidone on FKBP10 protein
expression relative to b-actin. Data are based on eight (IPF) or three (donor) completely independent experiments and are given as mean6 SEM.
Statistical significance between control and different concentrations of nintedanib or pirfenidone is indicated by horizontal brackets and asterisks.
Statistical analysis was performed by one-way analysis of variance (posttest, Bonferroni‘s multiple comparison test: comparison against control).
*P, 0.1, **P, 0.01, ***P, 0.001. The well-known effect of TGF-b1 on these transcripts and proteins was significant, but it is not specified in the
interest of clarity.
ORIGINAL RESEARCH
Knüppel, Ishikawa, Aichler, et al.: IPF Drugs Inhibit Collagen Fibril Formation 85
nintedanib pirfenidone
A B
ctrl
TGF-β
ctrl ctrl ctrl
- 
Δ
C
t (
H
S
P
47
-D
H
X
8)
tr
an
sc
rip
t f
ol
d 
ch
an
ge
H
S
P
47
4
8
6
IPF
– – – – – – – –+ + + + + + + +
ctrl
TGF-β
ctrl ctrl ctrl
– – – – – – – –+ + + + + + + +
- 
Δ
C
t (
H
S
P
47
-D
H
X
8)
nintedanib pirfenidone
Donor
0
0.5
1.0
1.5
nintedanib pirfenidone
TGF-β – – – + + + – – – + + + TGF-β – – – + + + – – – + + +
nintedanib pirfenidone
tr
an
sc
rip
t f
ol
d 
ch
an
ge
H
S
P
47
nintedanib pirfenidone nintedanib pirfenidone
ctrl
TGF-β
ctrl ctrl ctrl
– – – – – – – –+ + + + + + + +
ctrl
TGF-β 
ctrl ctrl ctrl
– – – – – – – –+ + + + + + + +
∼ 55
kDa
C
E
D
F
****
re
la
tiv
e 
ba
nd
 in
te
ns
ity
(H
S
P
47
/β
-a
ct
in
)
∼ 55
kDa
HSP47
β-actin
HSP47
β-actin
re
la
tiv
e 
ba
nd
 in
te
ns
ity
(H
S
P
47
/β
-a
ct
in
)
0
0.5
1.0
1.5
10
4
8
6
10*
*
****
0
0.5
1.0
1.5
0
0.5
1.0
1.5
Figure 5. Expression of the major collagen I chaperone HSP47 is reduced only on the transcript level by both drugs in IPF fibroblasts. (A–D) Quantitative
RT-PCR analysis of phLF isolated from (A and C) patients with IPF or (B and D) healthy donors treated for 48 hours with increasing concentrations of
nintedanib (0.01, 0.1, and 1 mM) or pirfenidone (100, 500, and 1,000 mM) in the absence or presence of TGF-b1 (2 ng/ml). Transcript levels of
(A and C) IPF and (B and D) donor phLF of HSP47 are shown as 2DCt values (A and B) as well as transcript fold changes (C and D) to show the effect
normalized to control. DHX8 was used as endogenous control. Data are based on seven (IPF) or three (donor) completely independent experiments and
are given as mean6 SEM. Statistical significance between control and different concentrations of nintedanib or pirfenidone is indicated by horizontal
brackets and asterisks for 2DCt values and by asterisks only for fold changes relative to 1. (E and F ) Western blot analysis of phLF isolated from (E )
patients with IPF or (F ) healthy donors treated for 48 hours with increasing concentrations of nintedanib (0.01, 0.1, and 1 mM) or pirfenidone (100, 500, and
1,000 mM) cotreated with or without TGF-b1 (2 ng/ml). Densitometric analysis and representative blots show the effect of nintedanib and pirfenidone on
FKBP10 protein expression relative to b-actin. Data are based on eight (IPF) or three (donor) completely independent experiments and are given as
mean6 SEM. Statistical significance between control and different concentrations of nintedanib or pirfenidone is indicated by horizontal brackets and
asterisks. Statistical analysis was performed by one-way analysis of variance (posttest, Bonferroni‘s multiple comparison test: comparison against control).
*P, 0.1, ***P, 0.001, ****P, 0.0001. The well-known effect of TGF-b1 on these transcripts and proteins was significant, but it is not specified in the
interest of clarity.
ORIGINAL RESEARCH
86 American Journal of Respiratory Cell and Molecular Biology Volume 57 Number 1 | July 2017
protein levels (Figures 5E and 5F), even if
both drugs showed effects on the transcript
level (Figures 5A and 5C). Again, this is in
contrast to previously reported results,
but may be due to higher pirfenidone
concentrations used in those studies
(21, 26).
Importantly, we found much fewer,
thinner, and aberrantly structured collagen
fibrils in the extracellular space of IPF
fibroblasts treated with nintedanib or
pirfenidone (Figure 6). This was
particularly unexpected for pirfenidone,
because we had observed only minor
effects on collagen synthesis and secretion.
As pointed out earlier in the text,
a partial explanation for this result may
be the observed down-regulation of type
V collagen, which, even if it represents a
minor constituent of collagen fibrils,
appears to be crucial for collagen
fibrogenesis (39). Because deficiency of
3-Hyp has been shown to have major
effects on lateral fibril growth (15), we
also assessed hydroxylation of three
3-Hyp sites in collagen I, a comparatively
rare collagen PTM, next to a lysyl
glycosylation site in collagen I. We did
not observe any effect of nintedanib or
pirfenidone on these PTMs of collagen I
(Figure E4). However, there are clearly
many more collagen PTMs to consider
and, in light of the recently reported
profibrotic properties of ECM of patients
with IPF (43), a broader PTM
fingerprinting of collagens in the context of
fibrotic disease would undoubtedly be
warranted.
Extracellular collagen fibril formation
is mainly an entropy-driven self-assembly
process (31). The so-called collagen
D-stagger is formed by specific interactions
of the residues along the triple-helical
molecules with regularly staggered ends.
After cleavage of the propeptides, the
collagen molecules become competent for
fibril formation. We took advantage of the
fact that this process can be studied in a
straightforward manner using purified
pepsin-digested collagen (27) and found
that low micromolar concentrations of both
drugs inhibited collagen I fibril formation
with comparable efficiencies in a dose-
dependent manner (Figure 7). Even if the
exact molecular mechanisms remain
obscure, it can be speculated that
pirfenidone and nintedanib directly bind
to collagen triple helices and mask or
alter interaction sites caused by changes
in hydrophobicity or charges on the surface
of the triple helix. Moreover, considering
that higher concentrations of pirfenidone
than of nintedanib were necessary to
achieve the same amplitude of effect,
nintedanib likely displays a stronger
affinity to collagen than does pirfenidone.
Finally, because pepsin-digested
solubilized collagen is used in our
cell-free system, it can be concluded that
the direct drug–collagen interaction takes
place in the collagenous region of
collagen and not in the telopeptides
and propeptides, which are typically
removed by pepsin digestion.
Interestingly, inhibition of collagen I
self-assembly has been proposed as a
strategy for antifibrotic therapy, but this
concept has received little attention in the
field of lung fibrosis thus far (44). Instead,
efforts have been undertaken to evaluate
the inhibition of collagen crosslinking by
the enzyme lysyl oxidase-like 2, notably a
step subsequent to spontaneous fibril
formation that stabilizes existing fibrils
(31, 45). Recently, however, a phase II study
with a monoclonal anti–lysyl oxidase-like
2 antibody was terminated because of a
lack of efficacy (46). Here we show, to
our knowledge for the first time, that
nintedanib and pirfenidone down-regulate
collagen V, a minor collagen important
for the initiation of extracellular
fibrillogenesis, and directly inhibit collagen
fibril formation. This suggests that both
therapeutics exert their antifibrotic
actions at least in part via the inhibition
of collagen fibril formation, which provides
additional support for the concept of
inhibition of collagen self-assembly as a
promising antifibrotic strategy. This is a
particularly interesting finding for
pirfenidone, in which the well-known
antifibrotic effects in vivo to date stay in
A
B
25
0x
10
00
x
control nintedanib pirfenidone
50 μm
10 μm
50 μm
10 μm
50 μm
10 μm
CBA
F
ib
ril
 th
ic
kn
es
s 
[n
m
]
0
control Nintedanib Pirfenidone
100
200
300
**
**
Figure 6. Nintedanib and pirfenidone decrease the number and thickness of collagen fibrils and alter
their appearance. (A) Scanning electron microscopy of extracellular matrix fibrils deposited by phLF
treated for 48 hours with nintedanib (1 mM, middle panel ) or pirfenidone (1,000 mM, right panel) and
TGF-b (2 ng/ml) showed fewer, thinner, and more frayed fiber bundles when compared with control
(left panel). Magnification is indicated on the left side (upper panel: 2503 ; lower panel: 10003 ).
Results shown are representative images of three independent experiments with similar results. (B)
Thickness of single fibrils was measured in scanning electron microscopy pictures in three
experiments using independently derived IPF fibroblasts. Statistical analysis was performed by a paired t
test. Scale bars, 50 mm in top panels of A–C, and 10 mm in bottom panels of A–C. **P, 0.01.
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sharp contrast to concentrations in the
millimolar range required to observe
effects on fibrotic marker expression
(19–21, 26, 36). Notably, we believe our
study is the first to offer evidence for
an antifibrotic effect of pirfenidone
in vitro, which occurs at a micromolar
concentration. For nintedanib, which affects
the intracellular collagen pathway more
strongly and in physiologically relevant
concentrations, the reduced fibril formation is
probably a combined result of intracellular
and extracellular events. Our findings
furthermore emphasize that collagen V plays
a hitherto underestimated role in fibrogenesis.
We observed only few differences
between IPF and donor fibroblasts regarding
the effects of nintedanib and pirfenidone on
the expression of the studied targets. The
most striking difference was observed in the
regulation of the collagen chaperone
FKBP10, the expression of which was
consistently down-regulated by nintedanib
in IPF fibroblasts without evidence for
down-regulation in donor fibroblasts. Even
more surprisingly, pirfenidone, which did
not affect FKBP10 expression in IPF
fibroblasts, decreased FKBP10 transcript
and increased FKBP10 protein levels in
donor fibroblasts. Another difference was
that nintedanib had a stronger negative
effect on COL1A1, COL3A1, and HSP47
transcription in IPF fibroblasts than in
donor fibroblasts; at the same time,
however, protein levels were unchanged or
regulated similarly. Finally, both drugs
down-regulated basal collagen I secretion
only in IPF fibroblasts and not in donor
fibroblasts. Apart from these differences, by
and large, the tendencies of the effects of
nintedanib and pirfenidone between IPF
and donor fibroblasts on fibrotic markers,
collagen chaperones, and collagen
secretion were similar. Notably, in a
previous study, we also observed that the
effects on collagen synthesis and secretion
were similar in IPF and normal control
fibroblasts, and we ultimately pooled those
results for data presentation (10). This is
also in agreement with the findings of two
previously published studies (25, 47).
Lehtonen and colleagues (47) examined the
effect of nintedanib and pirfenidone on
fibroblast and myofibroblast properties and
also observed only marginal differences
between cells from control and IPF lungs.
Hostettler and colleagues (25) studied
collagen secretion by nintedanib in phLF
and IPF fibroblasts and found that
collagen secretion was down-regulated to
the same extent in both cell types.
In conclusion, our findings provide
an overview and a direct comparison
of the effects of the Food and Drug
Administration/European Medicines
Agency-approved IPF drugs nintedanib
and pirfenidone on different stages of
expression and maturation of collagen in
primary human lung fibroblast derived
from patients with IPF as well as from
healthy donors. Nintedanib clearly was
more efficient than pirfenidone in
inhibiting profibrotic gene expression and
collagen secretion, both in terms of the
required effective concentration as well
as in the number, consistency, and
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Figure 7. Spontaneous collagen fibril formation is inhibited by both drugs in a dose-dependent manner. A collagen type I stock solution in 50 mM
acetic acid was diluted to a final concentration of 0.1 mM into a 0.1 M NaHCO3 buffer (pH 7.8) containing 0.15 M NaCl and 1 mM CaCl2 and heated up to
348C, followed by monitoring of absorbance (light scattering) at 313 nm. (A) Nintedanib (red, 0.5 mM [n = 2]; blue, 1.0 mM [n = 5]) and (B) pirfenidone
(red, 1.25 mM [n = 3]; blue, 2.50 mM [n = 2]; green, 10.0 mM [n = 3]) on collagen type I fibril formation in comparison to dimethyl sulfoxide control (black
[n = 4]) are shown. The resulting half-time values for fibril formation are given in Table 1.
Table 1. Half-Time Values for Fibril Formation (Fibril Formation50)
Concentration of
Indicated Drug (mM) Fibril Formation50 (min) P Value*
0 (DMSO control) 49.66 2.1
Nintedanib
0.5 55.66 2.1 n.d.
1.0 59.16 2.0 0.000218†
Pirfenidone
1.25 54.26 4.7 0.133
2.5 57.36 4.6 n.d.
10 61.66 3.1 0.00165‡
Definition of abbreviation: n.d., not determined (n = 2).
Nintedanib and pirfenidone increase half-time values for fibril formation (fibril formation50) dose
dependently. Half-time values for fibril formation (fibril formation50) are defined as the time at which the
absorbance reaches half the value of the total absorbance change. Data are derived from graphs
shown in Figure 7 and are presented as mean6 SD.
*Statistical analysis was performed on half-time values relative to DMSO control using one-way
analysis of variance.
†P, 0.001.
‡P, 0.01.
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magnitude of its effects in independently
derived IPF fibroblast lines. Finally,
nintedanib and pirfenidone inhibited
collagen fibril self-assembly, which
represents a novel antifibrotic mechanism
of action for both drugs. We suggest
two independent potential mechanisms
for this observation, namely, down-
regulation of collagen V and inhibition
of extracellular fibril formation by
direct interaction of the drugs with
triple-helical collagen. n
Author disclosures are available with the text
of this article at www.atsjournals.org.
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Figure 5. Effects of FKBP10 deficiency. FKBP10 deficiency leads to several antifibrotic effects based on 
altered collagen or fibrotic marker expression. FKBP10 loss reduces collagen secretion and collagen I, III, V, FN 
expression. Collagen V and FN in turn are needed for extracellular collagen I fibril formation in vivo. FKBP10 
downregulates collagen VI expression which in turn leads to reduced cell migration. FKBP10 might be needed 
to prevent HSP47 aggregation, which is needed for collagen triple helix formation, like FKBP10. P3H4 forms a 
complex with P3H3 and Cyclophilin B (CYPB) influencing LH1 activity. LH1 is needed for the generation of PTM 
in the helical regions of collagen. FKBP10 is a known modulator of LH2 activity. LH2 is responsible for PTMs in 
the telopeptide regions of collagen I, which are important in collagen fibril formation. Missing PTMs result in 
aberrant collagen fibril formation, followed by impaired collagen crosslinking and ultimately in an altered ECM 
topography. (Source: Larissa Knüppel) 
 























